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Abstract
Type 2 diabetes mellitus (T2DM) is a nation-wide prevalent chronic condition, which includes
direct and indirect healthcare costs. T2DM, however, is a preventable chronic condition based on
previous clinical research. Many prediction models were based on the risk factors identified by
clinical trials. One of the major tasks of the T2DM prediction models is to estimate the risks for
further testing by HbA1c or fasting plasma glucose to determine whether the patient has or does
not have T2DM because nation-wide screening is not cost-effective.
Those models had substantial limitations on data quality, such as missing values. In this
dissertation, I tested the conventional models which were based on the most widely used risk
factors to predict the possibility of developing T2DM. The AUC was an average of 0.5, which
implies the conventional model cannot be used to screen for T2DM risks. Based on this result, I
further implemented three types of temporal representations, including non-temporal
representation, interval-temporal representation, and continuous-temporal representation for
building the T2DM prediction model. According to the results, continuous-temporal representation
had the best performance. Continuous-temporal representation was based on deep learning
methods. The result implied that the deep learning method could overcome the data quality issue
and could achieve better performance.
This dissertation also contributes to a continuous risk output model based on the seq2seq model.
This model can generate a monotonic increasing function for a given patient to predict the future
probability of developing T2DM. The model is workable but still has many limitations to
overcome.
Finally, this dissertation demonstrates some risks factors which are underestimated and are worthy
for further research to revise the current T2DM screening guideline. The results were still
preliminary. I need to collaborate with an epidemiologist and other fields to verify the findings. In
the future, the methods for building a T2DM prediction model can also be used for other prediction
models of chronic conditions.
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Chapter 1: Introduction
Electronic health records (EHRs) are now being created, modified, used, and viewed by multiple
entities such as primary care, hospitals, insurance companies, and patients. More and more medical
information, including the patients’ health information, records of clinical decision-making, and
prescriptions, is collected and documented. The data volume of EHRs has increased exponentially
over the past several years. Besides the data volume, data complexity is also a challenge. The data
complexity comes from the knowledge domain, such as the meaning of the variable, representing
the variable, and using the temporal information in the dataset. For those challenges, machine
learning is a potential approach to learn some information from the complex dataset.
Because the EHR is a longitudinal record, different temporal representations can describe different
aspects of temporal information in the EHR, which can assist us in understanding the importance
of a particular variable with or without considering the previous information. Three temporal
representations were applied to this research. The research not only tests different types of
temporal representations but also creates a novel prediction model that can estimate a continuous
function for estimating the possibility of developing T2DM.
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Chapter 2: Literature Review
Chapter 2.1: The Definition of Diabetes Mellitus and Diagnostic Criteria
Diabetes mellitus (DM) is a wide-spread chronic disease. In this section, I will generally
introduce the definition of diabetes mellitus and its diagnostic criteria.

Chapter 2.1.1: What is Diabetes Mellitus?
Diabetes mellitus (DM) is a group of metabolic diseases characterized by hyperglycemia resulting
from a deficiency of insulin action, insulin secretion, or both. Diabetes mellitus can be classified
into four general categories 1) Type one diabetes mellitus (T1DM), 2) Type two diabetes mellitus
(T2DM), 3) Gestational diabetes mellitus (GDM), and 4) Specific types of diabetes due to other
causes[1]. Type one diabetes is caused by autoimmune beta-cell destruction leading to absolute
insulin deficiency. Type two diabetes is due to a progressive loss of beta-cell insulin secretion
frequently accompanied by insulin resistance. GDM is generally diagnosed in the second or third
trimester of pregnancy. In addition, patients with GDM have a high probability of developing
T2DM within the next several years[2]. Other types of diabetes are caused by monogenic defects,
disease of the exocrine pancreas, drugs, or chemicals. Among four different categories of diabetes,
both type one and type two are major concerns. Currently, DM can be diagnosed by some of the
methods described below.

Chapter 2.1.1: Current Diagnostic Criteria of Diabetes Mellitus
In 1997, the first Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
revised the diagnostic criteria by evaluating the three cross-sectional epidemiological studies
which focused on fasting plasma glucose (FPG) levels and the presence of retinopathy[3].
Retinopathy is the key factor which determines the acceptable threshold of a glucose level. The
three studies confirmed the long-standing diagnostic 2-h plasma glucose (2-h PG) value over
200mg/dL led to a significant increase in the risk of developing retinopathy. The older FPG value,
140 mg/dL, was noted to identify far fewer individuals with diabetes than the 2-h PG criteria. The
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committee decided to reduce the value of FPG from 140 mg/dL to 126 mg/dL. In 2009, the
International Expert Committee recommended the use of the Hemoglobin A1c (HbA1c) test to
diagnosis DM, with the threshold over 6.5%, and confirmed by American Diabetes Association
(ADA)[4]. Patients who present with severe hyperglycemic symptoms or hyperglycemic crisis can
be diagnosed by random plasma glucose (RPG) over 200 mg/dL. All criteria are listed in table 1.
Table 1.The Diagnostic Criteria of DM
Test Name
FPG

Range
>= 126 mg/dL (7.0mmol/L)

2-h-PG

>=200mg/dL (11.1mmol/L)

HbA1c

>=6.5%(48 mmol/mol)

RPG

>=200mg/dL (11.1mmol/L)

Criteria
Fasting is defined as no caloric intake for at least
eight hours.
Using 75 grams anhydrous glucose is dissolved in
water.
The method should be certified by NGSP and
standardized DCCT assay.
Patients should present severe hyperglycemic
symptoms or hyperglycemic crisis.

Chapter 2.2: The Prevalence and Economic Burden of DM in the U.S.
In this section, I will review the articles related to the prevalence of DM and the economic burden
in the U.S.

Chapter 2.2.1: The Prevalence of Diabetes Mellitus in the U.S.
Several studies, such as the National Health Interview Survey (NHIS)[5], National Health and
Nutrition Examination Survey (NHANES)[6], and Behavioral Risk Factor Surveillance System
(BRFSS) [7], are used to examine the prevalence and the incidence of DM in the U.S.. These
survey programs are sponsored by the Centers for Disease Control and Prevention (CDC). NHIS
is a large-scale cross-sectional household interview survey. NHIS collects information on
population disease prevalence, extent of disability, and use of health care services. The prevalence
information is based on self-reported diagnosis and other data. NHANES combines interviews and
physical examinations. The examinations include medical, dental, and physiological
measurements, including laboratory tests. The Behavioral Risk Factor Surveillance System
(BRFSS) uses nation-wide health-related telephone surveys that collect U.S. resident data
regarding their health-related risk behaviors, chronic health conditions, and use of preventive
services. This system currently collects 400,000 adult interviews each year in all 50 states. The
3

previous research focused on the residents in the U.S. including all ages, races, and genders. The
SEARCH for Diabetes in Youth was initiated in 2000 and funded by the CDC for researching the
incidence and the prevalence of diabetes for 0-19 years[8]. SEARCH primarily focuses on the
association between DM and DM-related risk factors including biological and socio-cultural risk
factors, quality of life, and mortality.
In the U.S., the CDC utilizes the NHIS to estimate the incidence of diagnosed diabetes including
T1DM and T2DM. The incidence of self-reported diabetes in 2012 was 0.71%, up from 0.35% in
1990.[9]. The incidence rate doubled in 12 years. Before 2016, the NHIS did not include a
supplemental question to distinguish T1DM or T2DM. There was no prevalence rate for T1DM
and T2DM before 2016. In 2016, the prevalence rate in U.S. adults of T1DM was 0.55%,
representing 1.3 million adults. Twenty-one (21) million U.S. adults were diagnosed with T2DM,
equal to 8.6% of the U.S. adult population. Three point three percent (3.3 %) of U.S. adults were
diagnosed with other types of DM[10].
Dr. Menke utilized NHANES to estimate the trend of DM and the prevalence in 2012 in the U.S.
His team indicated that from 1988 to 2012, the age-standardized prevalence in the U.S. increased
from 9.8% in1988-1994 to 10.8% in 2001-2002 to 12.4% in 2011-2012[11]. The upward trend
appeared in age groups, genders, racial/ethnic groups, and all education levels. The same dataset
also indicated sixty-four percent of DM patients were diagnosed, others were undiagnosed. In all
races, Hispanics have the highest age-standardized prevalence (22.6%)[12].
Dr. Mokdad used the BRFSS data in 2000 to estimate prevalence of DM from 184,450 adults
enrolled in this dataset. The estimated prevalence was 9.7%[13]. From the website of BRFSS, the
crude prevalence of DM increased from 9.5% in 2011 to 10.5% in 2016. In 2011, Mississippi
(12.4%), South Carolina (12.1%), West Virginia (12.0%) were the top three states with the highest
crude prevalence. West Virginia (15.0%), Alabama(14.6%), and Mississippi(13.6%) had the most
DM patients in the 2016 BRFSS survey data[13].
Currently more and more young patients develop diabetes. In 2009, the SEARCH for Diabetes in
Youth Study indicated the prevalence of DM in youths under the age of 20 was 0.2%[14]. Among
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those patients, 86% of them had T1DM, 10.8% of them had T2DM, with the remainder suffering
from other diabetes types. Based on this study, the researchers estimated 191,986 U.S. youth under
the age of 20 had diabetes in 2019. Most of them were diagnosed with T1DM.

Chapter 2.2.2: The Economic Burden of DM in the U.S.
The American Diabetes Association (ADA) published the economic cost of DM in the U.S. every
five years beginning in 2007[15]. The 2007 report includes both national level and state-level data
from NHIS, NHANES, Medical Expenditure Panel Survey (MEPS), National Inpatient Sample
(NIS), National Ambulatory Medical Care Survey (NAMCS), Ingenix MCURE database, National
Hospital Ambulatory Medical Care Survey (NHAMCS), National Nursing Home Survey (NNHS),
and National Home and Hospice Care Survey (NHHCS). In 2012[16], ADA added the American
Community Survey (ACS), Behavioral Risk Factor Surveillance System (BRFSS),
Optumlnsight’s de-identified Normative Health Information database (dNHI), the Medicare 5%
sample Standard Analytical Files (SAFs), and Current Population Survey (CPS) into the 2007
study’s datasets. In a recent publication, the ADA added the Medicare Current Beneficiary Survey
(MCBS) into the 2012 study datasets.
In 2007, the ADA utilized the NHIS (2004-2006) and NNHS (2004) to estimate the prevalence in
different age groups, sex, and race/ethnicity. The NHIS was applied to estimate the prevalence of
noninstitutionalized people. The ADA assumed the prevalence rate of DM of institutionalized
people was the same as noninstitutionalized people. The NNHS was utilized for analyzing the
prevalence of DM in nursing homes. The previous two datasets focused on diagnosed DM rather
than undiagnosed DM. The NHANES, combining interview and physical examinations, was used
to estimate undiagnosed prevalence. Based on the prevalence rate found in the previous three
datasets, the ADA further interpreted prevalence rate by merging U.S. Census Bureau population
estimates (2007) for a more accurate estimation of the national prevalence rate. After identifying
the national prevalence rate, ADA analyzed the medical cost for diabetes. For direct medical costs,
the ADA adapted MEPS for outpatient and the NIS for inpatient. For adjusting etiological fractions
which are important to analyze the attribution of health resource cost, the ADA decided to use
MCURE, a medical claim dataset enrolling 16.3 million beneficiaries in 2006. This resulted in
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relative attributions of health resources and costs for different medical conditions. These relative
attributions were applied to the NAMCS, NHAMCS, NHHCS, NNHS, and NHIS to estimate the
indirect costs of DM In 2012, ADA merged dNHI, a new dataset from MCURE database and SAFs
for adjusting etiological fractions. Moreover, the ADA started to use ACS and BRFSS to estimate
the prevalence rate of DM in the U.S. The ADA also decided to combine NHIS and CPS for more
precise estimation of the loss of national productivity. In 2017, ADA added MCBS for more
accurately estimation of prevalence rate of DM of state level[17].
The total estimated direct and indirect costs of T2DM are listed in the table 2. Each category
includes the detail cost estimation of each major category.
Table 2. The Estimated Economic Burden of DM in the U.S.
Summary
Total cost incurred by people with
DM
Total cost incurred by people with
DM attributed to DM
Total indirect cost of people with DM
Health Care expenditures
Institutional care
Outpatient care
Outpatient medications and supplies
Chronic complications
Neurological
Peripheral vascular
Cardiovascular
Renal
Metabolic
Ophthalmic

Year
2007
(U.S.D)
205 billion

2012
(U.S.D)
673 billion

2017
(U.S.D)
414 billion

116 billion

361 billion

237 billion

58 billion

69 billion

89.9 billion

65 billion
23 billion
28 billion

90 billion
31 billion
52 billion

76 billion
53 billion
106 billion

3.5 billion
3.0 billion
22.4 billion
3.6 billion
0.22 billion
1.04 billion

4.8 billion
3.8 billion
22.4 billion
5.2 billion
0.35 billion
1.8 billion

Not provided
Not provided
Not provided
Not provided
Not provided
Not provided

Chapter 2.3: The Medical Backgrounds of T2DM
In the previous two sections, I focused on what is DM and the severe current condition of DM. In
this section, I will give more attention to T2DM because T2DM is preventable. The following
sections include the disease path of T2DM, risk factors and complications of developing T2DM.
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Chapter 2.3.1: The Disease Path of T2DM
Prediabetes is a state of dysglycemia that precedes the development of T2DM[18]. Insulin
resistance and beta cell dysfunction are both key etiological determinants of prediabetes and
diabetes[19]. The concurrent deterioration in whole-body insulin resistance and beta cell secretion
can determine the transition from normal glucose tolerance (NGT) to impaired glucose tolerance
(IGT) over T2DM[20]. The distinct trajectories between whole-body insulin resistance and beta
cell function on individuals found to have diabetes is based on elevated FPG versus elevated 2-h
PG during the 75-g OGTT[21]. Insulin sensitivity declined more rapidly in individuals
accompanied with elevating 2-h PG by OGTT before diagnosing T2DM[22]. In contrast, beta cell
secretion was significantly decreased in the subgroups of T2DM with concurrent increasing FPG
before receiving T2DM diagnosis[23]. The phenomena of elevated FPG is called impaired fasting
plasma glucose (IFG), and the inflated OGTT is named as impaired glucose tolerance (IGT). In
previous studies, IFG is more associated with hepatic insulin resistance and excessive endogenous
glucose production[24] than IGT, which is characterized by skeletal muscle insulin resistance[25].
In addition, subjects with IGT have impaired first and second phase insulin secretion and IFG
presents as an isolated defect in first-phase secretion[26]. Individuals in the period of IFG or IGT
are considered as prediabetic patients[27]. Prediabetes is a general term to represent the condition
between normal glucose tolerance (NGT) and diabetes. Prediabetes is associated with a variety of
disorders usually considered with diabetes.

Chapter 2.3.2: The Risk Factors and Complications Associated with T2DM
From the World Health Organization definition, a risk factor is any attribute, characteristic or
exposure of an individual that increases the likelihood of developing a disease or injury[28]. The
definition of complication is an unanticipated problem that arises following, and is a result of, a
procedure, treatment, or illness. Combined with the disease path of diabetes, the risk factors of
T2DM might be the complications of prediabetes. The following section will illustrate the risk
factors, and complications of prediabetes and T2DM.
Risk factors associated with T2DM can be roughly divided into modifiable risk factors and
irreversible risk factors. Reversible risk factors include overweight/obesity, physical inactivity,
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hypertension, abnormal lipid profile, and socio-economic status[29]. Irreversible risk factors are
comprised of demographic factors, including age, gender, race/ethnicity, genomic, and family
history[30]. Prediabetes is currently considered to have a strong correlation with cardiovascular
disease, periodontal disease, cognitive dysfunction, retinopathy, neuropathy, nephropathy,
obstructive apnea, hypogonadism, and metabolic syndrome[31].
For modifiable risk factors, the following studies provide the association between those risk factors
and T2DM. Several studies indicated weight reduction significantly decreasing the possibility of
developing T2DM. Those studies were conducted across several countries including U.K., U.S.A,
Canada, Australia, Germany, Finland, the Netherlands, Singapore, Sweden, and China[32].
According to the CDC 2017 National Diabetes Statistics Report, based on 2011-2014 NHANES,
87.5% adults diagnosed with T2DM were overweight or obese[33]. Among those people
diagnosed with diabetes and overweight/obesity, 26.1% were overweight, 43.5% were obese, and
others were severely obese. MEPS provided another data source for profiling the correlation
between physical inactivity and diabetes. Compared with normal-weight active adults, the
multivariate adjusted odds ratio for diabetes was 1.52 for normal-weight inactive adults and 1.65
for overweight inactive adults[34]. Many years ago, several studies indicated hypertension is a
significant predicator of T2DM. Those studies were prospective studies with large cohorts.
Abnormal lipid profile including increased total cholesterol and reduced HDL increases the risk
of developing T2DM. Recently, fasting triglycerides are a new predictor of diabetes. Socioeconomic status is usually associated with physical inactivity, a lack of fresh fruit and vegetables,
overweight/obesity, and smoking which are all dominant risk factors for developing T2DM.
The irreversible risk factors of T2DM, including gender, race, age, and ethnicity, have different
contributions to different types of DM. The T2DM incidence rate is increasing in youth, especially
among some racial and ethnic groups with a disproportionately high risk for developing T2DM
and its complications: American Indians, African Americans, Hispanic/Latinos, Asians, and
Pacific Islanders. Older age is highly correlated with risks for developing T2DM. Males have a
slightly higher prevalence rate than females. A group of subsets of genetic variants are associated
with T1DM and T2DM. Genome-wide association studies have identified 130 genetic variants
associated with T2DM, glucose levels, or insulin levels, but those variants just explained 15% of
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disease heritability[35]. Most T2DM variants are located in noncoding genomic regions. Some
variants, such as KCNQ1, had strong parent-of-origin effects[36]. Unfortunately, most known
T2DM genetic variants were less successful than clinical risk factors (BMI, family history, glucose)
for identifying those at future risk for developing T2DM[37]. Family history of T2DM is still an
important risk factor. Based on the InterAct study, prominent lifestyle, anthropometric, and genetic
risk factors could explain only a marginal proportion of family history-associated excess risk[38].
The result inferred family history still remains a strong, independent, and easily assessed risk factor.

Chapter 2.3.3: The Association Between Diseases and Prediabetes
Prediabetes is the chronic condition which has a high possibility of developing T2DM in the future
but can be reversed by appropriate treatment or life style change. Several diseases have been
demonstrated to be associated with prediabetes. Understanding those relationships between those
diseases and T2DM can find some targets for preventing T2DM.

Chapter 2.3.3.1: The Association Between Cardiovascular Disease and Prediabetes
Several studies across different countries presented a strong relationship between prediabetes and
cardiovascular diseases. In the Whitehall study, the risk of cardiovascular disease was almost
double within subjects with IGT, then NGT[39]. Coutinho and colleagues carried out a metaanalysis enrolling 95,000 individuals followed for 12 years which recognized the correlation
between blood glucose and cardiovascular disease events[40]. The Austrian Diabetes, Obesity and
Lifestyle Study found cardiovascular disease mortality increased 1.6 times among patients with
IFG[41]. Ford and fellow researchers published a systematic review to examine the relationship
between prediabetes and CV risk[42]. The systematic review concluded the relative risk (RR) of
cardiovascular disease of IFG between 1.18 and 1.20. The RR of IGT was 1.20. Patients have IFG
and IGT where the RR of cardiovascular disease was 1.1. However, CV risks are not the only
ones[42].

Chapter 2.3.3.2: The Association Between Circulatory Disease and Prediabetes
Circulatory problems include retinopathy and neuropathy. Retinopathy is a common complication
of T2DM. In a study relating FPG and retinopathy, no clear threshold could be identified as the
point at which patients without diabetes (FPG< 7.0mmol/l) would be in danger of retinopathy
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occurring. The prevalence of retinopathy with the FPG below 5.6 mmol/l ranged from 7-13
percent[43]. For those with an age above 40, either FPG over 5.8 mmol/l or HbA1c above 5.5%
resulted in a significant increase in prevalence. Neuropathy is common in diabetic patients. Newly
diagnosed diabetic patients roughly with 1.18 -1.25 times have developed neuropathy compared
with non-T2DM patients. This phenomenon, considering the progress of DM, implied the
neuropathy might happen in the period of prediabetes. Chronic kidney disease (CKD),
characterized by albuminuria or reduced kidney function, is highly prevalent in diabetic and
prediabetic patients. A decrease in glucose tolerance steeply increased the prevalence CKD in a
population-based study. This study indicated the prevalence of CKD, compared with the nondiabetic group, increased from 1.2% with the FPG between 4.94 and 5.27 mmol/l to 4% when the
FPG is over 5.66mmol/l[44]. A study based on NHANES (1999-2006) indicated 17.7% of
prediabetic patients had CKD compared with only 10.6% of non-diabetic individuals[45].

Chapter 2.3.3.3: The Association Between Hypogonadism and Prediabetes
There is a bidirectional relationship between T2DM and male hypogonadism[46]. Cross-sectional
studies demonstrated that 25-40% of males with DM also had low testosterone levels[47]. Reduced
levels of testosterone have also been associated with insulin resistance[48]. Male individuals with
low testosterone also have a higher possibility of developing DM[49]. One study examined 221
middle-aged, male individuals without diabetes and identified an inverse association between
testosterone, FPG, and insulin resistance which is independent of body fat or abdominal fat[50].
The relationship between insulin resistance and testosterone raised the question of whether or not
there is a link between prediabetes and testosterone. Few studies have focused on this question. A
community-based cross-sectional study conducted by Goodman and colleagues examine the
association between androgen levels and glucose tolerance of male individuals over 55[51]. They
also found men with IFG or IGT had substantially lower total testosterone levels adjusted by age
and BMI. Another cross-sectional and longitudinal study investigated the impact of IFG on sexual
dysfunction[52]. Metabolic syndrome is associated with many diseases such as CVD and T2DM.
In addition, there is an overlap in the presence of prediabetes and metabolic syndrome[53].

Chapter 2.3.3.4: The Association Between Other Conditions and Prediabetes
Obstructive sleep apnea (OSA) is one type of sleep-disordered breathing (SDB) which is
characterized by a cessation of breathing while sleeping. This symptom is associated with T2DM,
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metabolic syndrome, hypertension, CVD, and insulin resistance[54]. OSA is believed to contribute
to IGT and insulin resistance. Twenty to sixty-seven percent of pre-diabetic patients also have
OSA [55]. Alshaarawy and colleagues utilized the NHANES dataset to answer the relationship
between SDB and prediabetes[56]. They evaluated 5,685 participants without diabetes and
indicated patients had more than 3 biomarkers of SDB, such as sleep duration less than 6 hours,
snoring, snorting, and daytime sleepiness, whose odds ratio of prediabetes were 1.6. Periodontal
disease is a prevalent complication of diabetes. Several studies indicated subjects with IGT had
severe periodontal inflammatory disease. However, other studies pointed out individuals with IGT
and NGT presented an identical periodontal status. Chronic hyperglycemia contributes to cognitive
dysfunction[57]. Clinically relevant diabetes-related cognitive decrements occur in two periods,
one in brain development in childhood, and another in aging when the brain undergoes
neurodegenerative changes. Hyperglycemia, in the absence of diabetes or IGT, has been
demonstrated to be associated with lower memory and reduced hippocampal volume[58]. Tan and
colleagues indicated diabetes and prediabetes, characterized by insulin resistance, hyperglycemia,
and hyperinsulinemia, were associated with decreased brain volume and reduced cognitive
function when presented in middle age[59].

Chapter 2.4: Some Biomarkers for Diabetes and Prediabetes
The definition of biomarker has changed over time. In 1998, the National Institutes of Health
defined the biomarker as “a characteristic that is objectively measured and evaluated as an
indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a
therapeutic intervention”[60]. WHO further extended this definition as “almost any measurement
reflecting an interaction between a biological system and a potential hazard, which may be
chemical, physical, or biological. The measured response may be functional and physiological,
biochemical at the cellular level, or a molecular interaction”[60]. In the clinical world, biomarkers
encompass everything from pulse and blood pressure through basic biochemistries to more
complicated laboratory results from blood or tissues. Biomarkers can be considered as surrogate
endpoints which represent health status. There are two requirements for biomarkers, one is
relevance and the other validity. Relevance is the biomarker informing clinical information which
can be used in clinical decision. Validity is the necessity of this biomarker for the endpoint[61].
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In addition to the pancreas, the liver also plays an important role in blood glucose homeostasis.
The liver is an important organ controlling gluconeogenesis, and it is also a target of end organ
damage from hyperinsulinemia[62]. Several biomarkers are associated with liver damage such as
alanine aminotransferase, gamma-glutamyl transferase, ferritin, plasminogen activator inhibitor 1,
tissue plasminogen activator antigen, C-reactive proteins, and triglycerides[63]. Those biomarkers
were increased in patients with dysglycemia before the diagnosis of T2DM. Some novel potential
biomarkers, from a nested case-control study of over 6000 patients, revealed several novel
biomarkers for T2DM such as adiponectin, CRP, ferritin heavy chain 1, interleukin-2 receptor
A[64]. Another study pointed out leptin, renin, IL-1RA, hepatocyte growth factor, fatty acid
binding protein 4, and tPA were associated with insulin resistance. However, a systematic review
indicated those novel biomarkers cannot provide substantial improvement for a prediction model
compared with well-known risk factors such as glucose, physical inactivity, and others[65].
Several studies inferred correlations between some biomarkers and prediabetes. Those biomarkers
were adiponectin, interleukin-1-receptor antagonist, metabolomics, fructosamine, and glycated
albumin, and Fetuin-A[66]. Adiponectin is a protein hormone produced by adipocytes which has
both insulin-sensitizing and anti-inflammatory effects. A case-control study analyzed the level of
adiponectin over time prior to diagnosis of T2DM where T2DM patients had a lower level of
adiponectin compared with non-T2DM patients over 13-year follow-up period[67]. Another
prospective study enrolled and followed up 5,085 IFG individuals over 4.4 years[68]. Male and
female subjects with the lowest adiponectin were 1.78 and 2.17 times likely, respectively, of
developing T2DM compared with those with the highest levels[68]. The interleukin-1-receptor
antagonist produced by adipocytes acts as a competitive inhibitor of Interleukin-1beta for its
receptor. Interleukin-1beta not only inhibits beta-cell function but also promotes beta-cell
apoptosis. In a nested case-control study subjects diagnosed with T2DM had a higher level
Interleukin-1-receptor antagonist up to 13 years prior to diagnosis with steep increases up to 6
years prior to diagnosis[69]. In the Framingham Offspring Study, 61 profiled metabolites within
378 subjects, half with DM and half without, three branched-chain amino acids and two aromatic
amino acids had higher concentrations up to 12 years before developing T2DM[70]. The KORA
cohort study pointed out lysophosphatidylcholine (LPC) 18:2, and acetylcarnitine were higher in
patients with IGT[71]. The EPIC-Potsdam study confirmed results of LPC 18:2. EPIC-Potsdam
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also pointed out sphingomyelin C16:1, and five species of acyl– alkyl phosphatidylcholines were
associated with increased T2DM risk[70]. Fructosamine is the measurement of glycated total
serum protein. Fructosamine and glycated albumin are the indicators of short-term glycemic
control. The ARIC study analyzed the association between fructosamine and incident DM which
pointed out patients with elevated 95th percentile at baseline with higher possibility of developing
DM[72]. Fetuin-A is a glycoprotein secreted by the liver which acts as inhibitor of insulin receptor
in the live and skeletal muscles. Stefan and colleagues found higher level of Fetuin-A were
associated with IGT, insulin resistance, and increased liver fat[73]. Ou and colleagues selected a
group of non-diabetic patients, 510 age- and sex- matched, with IGT had higher level of Fetuin-A
compared with NGT[73].

Chapter 2.5: The Duration of Prediabetes
Several studies tried to identify the average duration of prediabetes which can determine whether
clinicians have enough time to delay the onset of diabetes or cause the patient to revert to NGT.
Bertram My and colleagues found the average duration of prediabetes was 8.5 years in males aged
over 30 and 10.3 years in female aged over 30[73]. Jared and colleagues enrolled 3,628 individuals
aged 18-30 years and followed them for 25 years. They found the average duration of prediabetes
was 9.5 years[75]. Mohammed and colleagues identified the average duration of prediabetes was
1.9 years[76]. Based on those studies, clinicians might have sufficient time to delay or prevent the
progression to diabetes.

Chapter 2.6: T2DM Intervention and Prevention
It is important to identify persons at risk for the development of T2DM as early intervention can
delay or prevent the full onset of diabetes [32,77]. Several studies demonstrated applying lifestyle
intervention, pharmacologic therapies, or bariatric surgery can augment insulin sensitivity and
prevent beta-cell work overload[78,79]. In addition, when individuals decrease 5% of their body
weight, total body insulin sensitivity can improve by 30% [80]and the probability of developing
T2DM can be reduced by 58%[81]. Individuals enrolled in the Finnish Diabetes Prevention Study
were instructed to lose weight (>5% of total body weight), reduce total fat consumption (<30% of
total calories), increase fiber consumption (15 g for each 1000 kilocalories), and extend physical
activity time (30 min/d)[82]. They were followed for 3.2 years. People who complied with the
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instructions had lower cumulative diabetes incidence compared with the control group[83]. Other
studies such as the Da Qing study[84], Diabetes Prevention Program[81], The Indian Diabetes
Prevention Program[85] confirmed these results. Some studies indicated drug interventions such
as metformin[81,85], rosiglitazone[86], and acarbose[87] can also reduce the incidence of T2DM.

Chapter 2.3.7: Diabetes Prediction Models Overview
As stated previously, there are several risk factors for T2DM which overlap with prediabetes. All
of those findings suggest that using those risk factors to develop a T2DM prediction model can be
used to delay or prevent T2DM as early as possible. There are major three types of T2DM
prediction models: 1) prediction of the onset of T2DM, 2) prediction of the short-term
complications, and 3) prediction of the long-term complications. Models of prediction of the onset
of T2DM are comprised of two major categories: 1) diagnostic prediction model, and 2) prognostic
prediction model. The diagnostic prediction model can predict, for a given patient, the presence or
absence of T2DM. In contrast, a prognostic prediction model of T2DM predicts the possibility of
patients developing T2DM over the following several years. Diagnostic prediction models utilized
the data backward from the time of diagnosis to identify the disease path. Diagnostic prediction
models can also be applied for prevalence estimation, predicting the current diagnosis, and
identifying undiagnosed patients. Prognostic prediction models adapt currently available data for
predicting the risks within a specific period. Prognostic prediction models can be implemented for
assisting patients to understand future risks, as well as allowing time for lifestyle changes to
prevent or slow the disease. Currently, there are 18 T2DM diagnostic prediction models which are
listed in table 3 and 17 T2DM prognostic prediction models which are presented in table 4.
Table 3. The Name of T2DM Diagnostic Prediction Models, Number of Patients, and
Performance
Study Name
American Diabetes Risk Score[88]
Brazilian Simple Prediction Model[77]
Cambridge Risk Score[90]
Chinese Diabetes Risk Score[91]
Danish Risk Score[92]
Diabetes Risk Calculator[93]
FINDRISC[94]
DPP questionnaire modified[95]
Dutch Diabetes Risk Score[96]
German Diabetes Risk Score[97]

Number of Patients
3,770
1,224
1,077
4,336
6,784
7,092
4,435
435
1,434
25,167
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Performance
AUC 0.78
AUC 0.77
AUC 0.80
AUC 0.64
AUC 0.80
AUC 0.85
AUC 0.87
AUC 0.80
AUC 0.78
AUC 0.84

Study Name
Indian Diabetes Risk Score[98]
Indian Risk Score[87]
Kuwaiti Risk Score[100]
Oman Diabetes Risk Score[89]
Patient Self-Assessment Score[102]
Rotterdam Predictive Model[103]
Spanish Diabetes Risk Score[104]
Symptom-Risk Questionnaire[105]

Number of Patients
2,350
10,003
562
4,881
5,258
1,016
6,237
2,364

Performance
AUC 0.69
AUC 0.73
AUC 0.82
AUC 0.83
AUC 0.79
AUC 0.74
AUC 0.83
AUC 0.80

Table 4.The Name of T2DM Prognostic Prediction Models, Number of Patients, and
Performance
Study Name
San Antonio Diabetes Risk Score[106]
Chinese Diabetes Risk Score[107]
DESIR Diabetes Risk Score[108]
Thai Diabetes Risk Score[109]
Framingham Offspring Diabetes Risk
Score[110]
QDScore[111]

Number of Patients
2,903
2,960
1,863
2,677
3,140

Performance
AUC 0.85
AUC 0.702
AUC 0.85
AUC 0.74
AUC 0.85

2,540,753

India Diabetes Risk Score[112]
PROCAM Diabetes Risk Score[113]
Rancho Bernardo Diabetes Risk[114]
Score
Diabetes Population Risk Tool[114]
AUSDRISK[115]
KORA[116]
BRHS[117]
EPIC-Norfolk[118]
Tromso[119]
PREDIMED scores[120]
Taiwan Risk Scores[121]

3,094
3,737
1,549

D Score (Female 2.11, Male
1.97)
AUC 0.70
AUC 0.79
AUC 0.71

9,177
6,060
873
6,927
12,519
26,168
1,381
73,961

AUC 0.77
AUC 0.78
AUC 0.76
AUC 0.77
AUC 0.76
AUC 0.84
AUC 0.641
AUC 0.83

Many previous studies have adapted logistic regression and survival analysis as two major tools
for building T2DM prediction models. Other people tried to utilize several machine learning
algorithms for building a T2DM prediction model. Those machine learning algorithms have been
tested by the Pima Indian Diabetes dataset including eight variables and 768 individuals. The
variables included times of pregnant, 2hr-OGTT, blood pressure, skinfold thickness, 2-hr serum
insulin, BMI, family history of DM, and age. The results of each study are listed in Table 5.
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Table 5. The Result of Pima Diabetes Dataset Over Different Machine Learning
Algorithms
Method
MFNNCA[122]
ANFIS[124]
MLP[125]
ARTMAP-IC[126]
GCS[128]
CART[129]
LVQ[129]
CART-DB[130]
MKS-SSVM[131]
LDA-ANFIS[133]
Semi Naïve Bayes [134]
MLPNN[135]
MME[123]

Accuracy
80.07%
98.14%
77.08%
81.00%
73.8%
72.8%
75.8%
74.40%
93.20%
84.61%
76.0%
91.53%
99.17%

Method
GRG2[123]
GRNN[125]
RBF[125]
MEA[127]
KNN[129]
MLP[129]
LDA[129]
SSVM[131]
PCA-ANFIS[132]
Naïve Bayes[134]
C 4.5[134]
ME[135]
ESOM[128]

Accuracy
81.25%
80.21%
68.23%
80.07%
77.0%
75.2%
77.5%
76.73%
89.47%
74.5%
76.00%
97.93%
78.4%

After entering the big data era, more data and methods are available for building prediction models.
The following section focuses on different aspects of developing a T2DM prediction model. The
first part is types of datasets utilized, including, but not limited to, survey, clinical trials, electronic
health records, and claim datasets. The second part examines the methods applied to the previously
mentioned dataset types. Those methods encompass statistical methods, machine learning
algorithms, and deep learning methods.

Chapter 2.8: Data Types in Developing a T2DM Prediction Model
The data sources for T2DM prediction model studies can be generalized into cohort studies, survey,
EHR (EMR), claims data, and miscellaneous data types. The definition for cohort study is “an
outcome, or disease-free study population first identified by the exposure or event of interest and
followed in time until the disease or outcome of interest occurs.” Based on this definition, most
previous T2DM prognostic prediction models are based on cohort studies. Those cohort-based
prognostic studies can be divided into two categories. One is cohort derivation study and the other
is cohort validation study. The difference between them is the study purpose. The purpose of a
cohort derivation study is to develop a new prediction model. The cohort validation study tests and
calibrates an existing model for general usage. Generally speaking, the data for a cohort derivation
study comes from a clinical trial. The data for a cohort validation study is typically derived from
another clinical trial, routine health checks, or a primary care database. The prediction model from
16

a cohort derivation study is usually summarized by risk scores. For example, the San Antonio
Diabetes Risk Score was derived from the San Antonio Heart Study. This study originally collected
data from patients with circulatory system diseases like hypertension, heart failure, and others. A
survey is another data source for the T2DM prediction model. The National Health and Nutrition
Examination Survey is an example of survey data. This survey is conducted by the CDC to identify
the health and nutritional status of adults and children in the U.S. The advantages of these two
types of data are low missing values and high completeness. However, the limitation of these two
types of data are low sample size and other missing information due to variables designed prior to
the data collection. EHR and claims data sets are not collected for research purposes. The
advantages of those two types are high sample size and more comprehensive information. The
main disadvantage is a high number of missing values.

Chapter 2.9: Pros and Cons of EHR Data in Clinical Research
EHRs provide opportunities to enhance patient care, improve clinical practice, and identify
patients eligible for clinical research. EHRs, in addition, may assist in the assessment of whether
new treatments, repurposed drugs, or innovative healthcare delivery models can improve outcomes
and result in cost savings. However, even with the previously mentioned benefits, EHRs still have
some disadvantages such as data quality and validation, high proportion of missing value,
heterogeneity among systems, and system knowledge. This paragraph will review the pros and
cons of EHRs and the different methods and applications between EHRs and traditional
epidemiologic methods.
EHRs have been widely utilized to support observational studies, either as stand-alone data or in
combination with other datasets. In observational studies, EHRs can minimize the need for
duplicate data collection and accumulate large amounts of medical information throughout the
patient’s life by using the existing informatics infrastructure. In some countries, EHRs can link to
other types of datasets such as general population health and lifestyle surveys, disease registries,
and data collected by other sectors. EHRs can be used for monitoring post-marketing safety
surveillance and signal detection because EHRs can provide realistic rates of events. National
patient registries extract data from EHRs for evaluating the guideline adherence and effectiveness
of performance improvement initiatives. EHRs, however, still have strong limitations for
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prospective studies. For clinical trials, EHRs can generate a list of qualified patients for specific
clinical research which is widely implemented. In clinical trials, there are two main categories.
One is pragmatic trials which are designed for examining the effectiveness of interventions in reallife practice conditions and another is explanatory trials which aim to test an intervention which
can work under several optimal situations. The National Institutes of Health (NIH) Care Systems
Research Collaboratory and the Patient-Centered Outcomes Research Institute have both applied
EHRs on pragmatic trials. EHRs can also support conventional randomized controlled trials for
collecting electronic case report forms when data collection is focused and limited to critical
variables which are consistently collected in routine clinical care.
The first limitation of EHRs is data quality and validation. One data quality problem with EHRs
comes from coding inaccuracies or bias introduced by the selection of codes driven by billing
incentives rather than clinical needs. Data quality issues can be further divided into data accuracy,
data completeness, data consistency, and data credibility. The data accuracy problems come from
coding errors. Internal validation and external validation can, to some extent, overcome this
problem. Missing values are the key challenge for data completeness. Values may be missing
because an event did not happen or external (e.g., imputation failure) or internal (e.g., patient
refusal to provide data) factors. Generally speaking, there are three categories of missing values:
data missing completely at random (MCAR), data missing at random (MAR), and data missing
not at random (MNAR). Several methods can mitigate the effects of missing values including data
triangulation, surrogate elements which represent missing variables of interest, and statistical
methods. Statistical methods enroll complete case analysis, available case analysis, mean/mode
substitution, regression imputation, multiple imputation, and maximum likelihood. Data
granularity and data measures are two major aspects of data consistency. Data granularity refers
to the degree of detail of a variable of interest within the EHR and the consistency of variable
granularity across databases or secondary data sets. Data measures indicate the consistency of
variable’s unit or reference range within the same dataset or across different datasets. Data
credibility is defined as the overall plausibility or reliability of the data. The degree of data
reliability is influenced by data sources, current domain knowledge, and user-perceived reality.
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Chapter 2.10: The difference between Traditional Epidemiology Study and EHRs
Epidemiology Study
Current FDA recommended using EHR in clinical investigation[136] and combining real-world
evidence to remove the barrier between clinical trials and clinical care[137]. From the current FDA
perspective, there are several differences between EHR based trial and clinical trials. Rob Califf,
FDA Commissioner, said” The most useful source of knowledge will come from randomization in
the context of clinical practice”. Understanding the difference between EHR based trial and
traditional clinical trial are helpful in explaining the results into the healthcare contexts. The table
6. outlines the questions the EHR could and could not answer[138].
Table 6.The difference of methods and applications between EHRs and traditional
epidemiologic methods
Design Factor
Original
Purpose
Cost
Access
Study Design

Traditional Epidemiology Study
Research; Primary data collection

EHRs Epidemiology Study
Clinical care; Secondary data usage

More expensive
Public
Prospective cohort, nested case-control,
cross-sectional

Less expensive
Restricted
Prospective or retrospective cohort,
nested case-control, cross-sectional less
common

Time Frame

Waiting until outcomes occur; restricted
by funding

Restricted by date of EHR
implementation

Population

Based on recruitment; fewer participants;
bias from incentives or healthy volunteer
effects

Based on healthcare system; more
participants; various population

Family Data
Follow-up

Sometimes available
Scheduled with specific timing; restricted
by funding

Available
Occurs during health care encounters;
with more individual encounters but
unspecific timing

Data
Collection and
Storage

Established protocol; robust approach for
data collection; with primary focus and
specific measurements

Recorded during encounter with varying
levels of detail; stored in diagnosis,
laboratory results, and ects

Conditions
captured

Any outcomes and all severities as
documented at beginning with clear
ascertainment

Only outcomes requiring care by
physician; missing value
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Design Factor Traditional Epidemiology Study
Outcome
Consistent outcome definition over all
Ascertainment participants

EHRs Epidemiology Study
Based on physician-specific diagnosis,
and other enriched information e.g., lab
results or medications

Clinical
Covariate
Ascertainment

Prespecified variables

Whole EHR but not random, confounded
by disease severity and other factors

Non-clinical
Covariate
Ascertainment

Prespecified variables

Limited or missing

Internal
Validity

Attrition: Participants must return for
study visits.
Statistical regression: Participants with
extreme initial values will regress toward
the mean on subsequent visits
Data Collection: Standardized across
sites
Nonparticipation bias: Systematic error
related to participants; participants with
certain characteristic might drop out

Attrition: Participants will continue as
they remain in health care system.
Statistical regression: Not necessary
Data Collection: Varied by different
providers
Nonparticipation bias: systematic error
related with healthcare system itself,
participants
Recall bias: reduced by longitudinal
EHR

External
Validity

Participants must agree to join;
participation rate declines overtime

Participants must be enrolled in the
health care system

Chapter 2.11: Current status of EHRs in T2DM Clinical Research
Currently, there are 114 articles which utilize EHRs for T2DM research[139]. In those articles, the
research topics can be grouped into following fields: epidemiology, prevention, susceptibility,
diagnosis, prognosis, complications, medication treatment, medication side effect, non-pharmacy
intervention, and insurance-based service delivery. The major reported barriers are missing values
(e.g., no related information of glucose values, limited information about complications, and death
reasons). Other major barriers are limited information on medication compliance, misclassification
of diabetes, data extraction problems of unstructured data, lacking longitudinal data in certain
EHRs, and fragmentation of patient information.

Chapter 2.12: Current Progress of Temporal Representation in the EHR
There is a variety of temporal information incorporated in the EHR. However, how to represent
the temporal information can still be a challenge. EHRs keep all available patients’ information in
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each visit. For each visit, EHRs store information including multiple medical concepts such as
diagnosis, medication, and procedure codes. The variation of each visit including the changing
records of diagnosis, medications, and lab results implies a temporal pattern which can be used to
understand patients' health condition over time. For example, the variation of the results of HbA1c
over several time points can deliver more information for machine learning algorithms to build a
model for early detection.
The records of patient’s visits provided two major relational information types, namely sequential
order of visits and co-occurrence of the codes within each visit. The sequential order of visits might
provide the progression of health conditions. Several papers utilized the sequential order of visits
for training the representation of medical concepts. The medical concepts include diagnosis,
medications, laboratories, vital signs, and procedures. The researchers used a high-dimensional
representation for indicating each medical concept. Those high-dimensional representations were
based on the sequential order of visits which have carried temporal information. Several methods
can be used to represent this temporal information. This dissertation will start with the most
popular method "word2vector (w2v)".
Word2vector (w2v) has two major methods. One is the "Skip-Gram" model and the other is
"Continuous Bag of Words (CBOW).” Both models were types of word2vector models. The skipgram model looped on the word of each sentence and tried to use the current word to predict its
neighbors. In contrast, CBOW model used the current word's neighbors to predict the current word.
Both models used a parameter to determine how many words should be considered. This parameter
was called "window size". Several papers used "Skip-Gram" model to train medical temporal
concepts. One of the papers used several data sources including medical journals (OHSUMED
dataset), medical claims data, and medical narratives for training the concepts[140]. Medical
claims data, and medical narratives suffered duplications which might affect the temporal
distributional pattern in an uninformative way. They also assumed the ordering of the events which
happened in a short period of time may not be important. By these two assumptions, they
partitioned the medical events of medical claims data, and medical narratives into several time
intervals, removed duplications within each period, and put the data into the "Skip-Gram" model.
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The previous example is a type of consideration of time. Adler Perotte in his paper "Parameterizing
time in electronic health record studies" proposed the EHR has two types of time[141]. One is
"clock time", and the other is "sequence time". People measured medical concepts (e.g. HbA1c)
in "clock time" under the time units such as seconds, days, months, or years. "Sequence time", in
contrast, measures medical concepts (e.g. HbA1c) between the members of any pair. The members
of any pair might be two clinical visits or two laboratory orders of the same laboratory. In their
research, they compared the variance of median absolute value as an outcome of four medical
laboratories including creatinine, glucose, sodium, and potassium over time. For the predictors,
they measured the variance of the previous four medical laboratories within two consecutive
measurements of each patient under "clock time" and " sequence time" and spread the variance
into 10 bins. Under this experiment, they found "sequence time" produced the most stationary
series. In time series analysis, stationary means the variance is consistent over time and the
abnormal variance is easy to identify.
Continuing from the previously mentioned two types of time, Edward Choi and colleagues
developed two types of medical concepts representation. One is Med2Vec model[142], and the
other is GRAM model[143]. In Med2Vec model, they used binary representation to represent
medical concepts in each visit as a binary vector. This binary vector went into multiple layer
perceptron (MLP) to get a condensed vector and used the "Skip-Gram" model to optimize it. In
Med2Vec model, they indicated this method not only considered the sequential information
(sequence time) but also encompassed the concurrence information within each visit. In GRAM
model, they incorporated ontology information into training temporal medical concepts. The
ontology information utilized in this research is ICD-9-CM/PCS, which has a parent-child
hierarchical structure. They combined ontology information with the Glove[144] method to
improve the performance of the prediction model by more than ten percent.
Besides using previous methods, some researchers started to apply Convolutional Neural Network
(CNN) to generate the temporal representation of medical concepts. Phuoc Nguyen and colleagues
developed a deep learning model called "Deepr"[145]. This model combined "w2v" and CNN to
create a new model for learning temporal medical concepts. The structure of this model separated
the timeline of EHRs into several intervals and aggregated all medical information into those
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intervals. The medical concepts in each interval will get high-dimension representation from
"w2v". CNN processed the representation of all medical concepts within each period and applied
"max-pooling" method to summarize all information based on all intervals. "Deepr" can generate
a more accurate pattern of readmission compared with traditional methods.
Recently unsupervised machine learning methods applied to EHRs had been under-developed.
"Deep Patient " is a good example to illustrate how to apply a stack of denoising autoencoders to
learn temporal medical concepts[146]. This research used 704,582 patients with 41,072 clinical
descriptors as a training dataset. The clinical descriptions encompassed diagnosis codes,
medications, lab tests, vital signs, and clinical notes. All clinical notes used LDA model to capture
300 topics. Eighty-one thousand, two hundred fourteen, (81,214) patients were used to validate
and test the model. This research indicated that the representation from "Deep Patient" achieved
higher accuracy compared with representations generated by K-means, PCA, and GMM. Takayuki
Katsuki and colleagues used Stacked Convolutional Autoencoder (SCA) to extract interpretable
temporal medical concepts representation[147]. They focused on lab tests of diabetic nephropathy
patients. A 2-D matrix was used to describe each patient. One dimension of this 2-D matrix was
time, and the other is lab tests. They found several temporal medical concepts associated with
diabetic nephropathy, such as CRP, EGFR, and amylase, had some interesting temporal patterns.
Attention mechanism is an emerging field for developing temporal medical concept
representations. The attention mechanism can capture global information rather than depend on
the information provided by the hidden state for better prediction. Yuan and colleagues utilized
this mechanism combined with "CBOW" to generate a model called Medical Concept Embedding
with Time-Aware Attention[148]. In this paper, they categorized all medical diagnosis code into
the following three types 1) Stable influence, 2) Peak influence, and 3) Sequela influence. Laura
and colleagues considered consequent visits had some temporal correlations within them and
attention mechanism can capture those temporal correlations[149]. The researchers aggregated all
EHR's medical concepts into several continuous periods and utilized the attention mechanism to
seize that information and processed that information by RNN and additional attention mechanism.
All of EHR's medical concepts were represented by "word2vector".
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The previously mentioned works mainly focused on medical concepts including diagnosis codes,
medications, and others. The results of those medical concepts were categorized into binary values
or categorical values rather than continuous values. For monitoring the trends of lab tests or vital
signs in real-time, this is not an appropriate approach. One of the major challenges is missing
values due to policies or data collection periods. Cara O’Brien and colleagues found a Gaussian
processes/RNN model which can handle missing value and can perform imputation based on
Gaussian distribution[150]. They compared their model with RF, LASSO model and traditional
sepsis prediction model and found Gaussian processes/RNN model had a better performance.
Based on the same work, Benjamin M. Marlin proposed the use of Radial Basis Function Network
to replace Gaussian processes and found the model performance was better than others[151]. Other
researchers proposed the use of "Mixtures of Expected Gaussian Kernels" to solve continuous
variables with irregular sampling time and the high proportion of sparsity[152].

Chapter 2.14: Current Progress of Deep Learning Models in the EHR
From 2012 to 2017, the annual number of deep learning papers was growing[153]. Those papers
covered topics ranging from concept representation, phenotyping, information extraction, and
prediction, to deidentification. The methods utilized by those papers included RNN, CNN,
autoencoder, Boltzmann Machine, Deep Belief Network (DBN), and Multilayer Perceptron. In
this section, I focus on the prediction models.
Based on the prediction outcome type, we can categorize all papers into two categories, one is
static outcome prediction and the other is temporal outcome prediction. Static outcome prediction
is predicting a specific outcome without considering temporal constraints. The medical concept
vectors generated by "skip-gram" had been demonstrated with better performance for predicting
health failure in SVM, MLP, logistic regression, and KNN[154]. Besides "skip-gram", DBN can
be trained with medical concept vectors and present better precision when compared with SVM,
or RF[155]. Stacked Sparse Auto Encoder classifier and Stacked Restricted Boltzmann Machine
classifier combining with word2vector model, TF-IDF, and PCA model also demonstrated better
performance in predicting healthcare-associated infections[156].

24

Temporal outcome prediction can predict the outcome, or onset within a specified time interval,
or make a prediction based on time series data. Most temporal outcome prediction models were
based on RNN. Lipton and colleagues used LSTM networks to predict multiple labels prediction.
In the final step, this network only predicted one of 128 diagnosis codes at the final output but this
network also used target replication at each timestep for handling the less-common diagnosis codes
as a regulation[157]. Doctor AI was another example which used one, or multiple RNN layers
used hidden states, to predict the diagnosis codes and the medication codes by Softmax function
and to predict the time duration between two visits by ReLU function[158]. RETAIN advanced
this idea and incorporated the attention mechanism for building the interpretable model[159].
Dipole model was Bi-LSTM RNN model combining with several different types of attention
mechanisms including 1) location-based attention, 2) general based attention, 3) concatenationbased attention[160]. DeepCare created two separate vectors per patient admission. One is for
diagnosis codes and the other is for intervention codes. This model also considered time decay
effects after max-pooling layer[161].
CNN is a famous deep learning model which is widely applied to medical image
classification[162],

abnormal

EGG

detection[163],

medical

concept

embedding

and

classification[164], and prediction models. The following is the review of EHR prediction models
based on CNN. Multi-layer convolutional neural networks is a deep learning method widely
applied to text mining, image classification, and other fields. Recently, this method was combined
with word2vector to build an EHR prediction model which outperformed other traditional
machine learning methods[165]. CNN was also used to predict heart failure, kidney failure, and
stroke by different lengths of kernel to capture temporal information within a time window. The
performance, however, lagged behind Bi-LSTM[166]. Word2Vector, grouped code Vector, and
binary vector combined with CNN respectively had also been tested for the early detection of heart
failure [167]. MATCH-Net is a model which combines CNN and survival analysis. The CNN part
extracts temporal information, overcomes the missing value effects, and generates the risk score
at each time point[168].
Beyond RNN and CNN, other deep learning algorithms have been used to build prediction models
based on EHR data. The first example is Hidden Markov Models (HMM). HMM had been
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implemented to predict the progress of COPD[169]. Another example is using HMM to model the
treatment pathways under real patient data[170]. Depth Belief Network (DBN) is another wildly
used deep learning model. DBN started to build a model for forecasting cardiovascular disease
from attributes extracted from the EHR including age, gender, serum cholesterol, ST wave
depression, and other features[171]. Multiple DBNs are used for processing different information
inputs and generating predictions from each source. The outputs from DBNs can be further
processed by Dempster-Shafer theory to predict the stage of prostate cancer [172]. Generative
adversarial network (GAN) is a semi-supervised deep learning method which can train a model by
real example and GAN generated examples. The final model should distinguish the real example
and GAN generated examples in the end. Most GAN models are based on images and ehrGAN is
the first model of GAN based on EHR[173]. In ehrGAN model, the research found some diagnosis
codes such as hypothyroidism, hypertension, and other variables related with the previous two
conditions prevalent in the dataset which might imply those diagnosis codes are associated with
DM. The GAN models based on EHR had a limitation of missing values. For overcoming this
problem an autoencoder had been introduced for imputation, and the GAN learned the dataset with
imputation[174].
Graph Augmented Memory Networks is a state of the art deep learning method which can
incorporate domain knowledge and EHR together and recommend the best strategy of
prescriptions[175]. The original idea came from graph CNN which can generate embedding for a
node base on nearby nodes. This paper used the characteristic to generate a graph to represent
drug-drug interaction[176].

Chapter 2.15: The Implications of Temporal Representation for T2DM in the EHR
Generally speaking, EHRs hold an amount of temporal information for mining the progress of
diseases. The progress of a disease can be summarized as a phenotype for further research. Current
EHR-based prediction models focus on clinical events likelihood either within an unspecified time
period (i.e., at some unknown future point) or with a fixed period (i.e., in the next two years).
Those models consider utilizing the whole information or using the latest information. They may
or may not explain how the temporal information affects the model. Because the temporal
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information can indicate, to some extent, the variance of some variables or lasting some chronic
conditions might be useful for further research.
Different types of temporal representation can assist machine learning algorithms to learn different
types information from the data. Understanding how different types of temporal representation
affects machine learning algorithms can give us hints how to utilize EHRs in the future. For
achieving this goal, this dissertation will separate this goal into three specific aims.
Aim 1. Running the three approaches 1) Non-Temporal, 2) Interval-temporal and 3) Continuoustemporal representation on the University of Texas Physician’s development dataset (UTP dataset).
Aim 2. Running the three approaches 1) Non-Temporal, 2) Interval-temporal and 3) Continuoustemporal representation on Cerner Health Facts validation dataset (CHF dataset).
Aim 3. Identifying the patterns or algorithms for the early identification of T2DM patients.
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Chapter 3: The Comparison of Different Types of Temporal
Representation over Development and Validation Dataset
Chapter 3.0: Overview
This study utilizes two datasets: the UT Physician (UTP) dataset and Cerner Health Facts (CHF).
The datasets are summarized using descriptive statistics. In order to capture and apply temporal
information, three types of temporal representation will be developed and applied to this research,
encompassing non-temporal representation, interval representation, and continuous representation.
I will compare the difference between the two datasets, list the performance of the model over two
datasets, and discuss the results.

Chapter 3.1: Running the Three Approaches on UTP Dataset
Chapter 3.1.0: Introduction of UTP
The UT Physician dataset encompasses several clinical information inputs such as Allscripts,
Centricity, and axiUm. Allscripts is currently the EHR system for the UT Physician Faculty
Practice, which includes records of clinical notes, diagnoses, medications, results of laboratory
tests, and vital signs. Centricity is a GE billing system that provides information related to claims.
axiUm is an EHR system currently implemented in the UT Dental School. This research primarily
uses the information from Allscripts but excludes clinical notes. The transition to a new diagnostic
coding system might affect the consistent meaning for a given condition. To avoid this issue, this
research only utilized the data before Oct/01/2015, which was the official date of the ICD-10CM/PCS implementation. Allscripts before Oct/01/2015 only had 820,217 patients who had at
least one datum. In those patients, 37,907 patients were T2DM patients, 723,634 were non-T2DM
patients, and others were T1DM patients or prediabetes patients. One challenge is that some
patients did not routinely visit the primary care clinics, resulting in missing information in the
EHR. For those patients, we cannot make reliable predictions. In this research, we excluded the
patients who had fewer than ten office visits between Jan/01/2000 and Oct/01/2015. The qualified
patients were 121,621 patients. Of those patients, 9,579 were T2DM patients and 112,052 were
non-T2DM patients
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Chapter 3.1.1: The Demographic Information of UTP Datasets
The following sections will illustrate the demographic constitution, the frequency of diagnosis,
medications, laboratory, and vital signs. This section will also provide the proportion of the
missing values of some essential measurements such as height, weight, and blood pressure of both
datasets. The first sections are the summary of demographic information of the two datasets. The
demographic information includes race, gender, and age when enrolled in this dataset.
Chapter 3.1.1.1: The Information of Demographic – UTP
Figure 1. The Summary of Demographic Features - UTP

Fig1.A is the race proportion of UTP dataset, the figure excluded the race below 1% of the
dataset. Fig1.B is the gender proportion of UTP dataset, the figure excluded the gender below
1% of the dataset. Fig1.C is the age proportion of UTP dataset when entering this dataset.
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Chapter 3.1.1.2: The Information of Years of Data – UTP
Figure 2. The Summary of Proportion of Patient with Datum Over Years - UTP
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From figure 2, the number of patients with available data drops as you go back through the years.
Less than half of the patients had more than five years of data in the UTP dataset. This is the
limitation for building a long-term prediction model.
Chapter 3.1.2: Methods
Handling EHRs, which involve complex datasets, includes a number of issues such as patients
returning irregularly, data representation, determining the final status of patients, defining
experiment schemes, and analysis methods. The analysis methods in this section focus on several
machine-learning algorithms, including deep-learning methods.
Chapter 3.1.2.1: Chronic Condition Indicators Imputation
For solving the problem in which patients did not return regularly, I introduced the Chronic
Condition Indicator (CCI) to perform condition imputation. CCI is maintained by The Agency for
Healthcare Research and Quality (AHRQ)[177]. CCI provides an approach for researchers to
categorize approximately 14,000 ICD-9-CM diagnosis codes into two major categories: chronic
and not-chronic conditions. CCI also classifies chronic conditions into 18 body system categories
to imply which system is affected by a chronic condition. The definition of a chronic condition
used by the CCI is a condition which can last 12 months or longer and meets one or both of the
following tests: (a) it places limitations on self-care, independent living, and social interactions;
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and (b) it results in the need for ongoing intervention with medical products, services, and special
equipment. Based on this definition, I assumed the patients with a chronic condition would
continue having this condition until the next visit. More details can be found in Figure 3. In Figure
3, a patient received the hypertension diagnosis code in the first and the third year but did not
provide any information in the second year. This will be an information gap in the second year.
With the assistance of CCI, we can still assume this patient had a chronic condition even though
we did not have any information. I did not adapt using the previous codes because we did not know
the exact status at that time point.
Figure 3. The Illustration of CCI Imputation

Chapter 3.1.2.2: Data Value Representation
This research focused on using structured data rather than unstructured data. The structured data
encompassed records of diagnosis, medications, laboratory, vital signs, and demographic
information. For diagnosis, medication, and demographic information, I used binary representation
(yes/no) to represent this information. For laboratory and vital sign information, I used data
binning and min-max normalization to present the information. The value of records of each
variable was in six categories from two standard deviations below the average to above two
standard deviations above the average. All records of the variable determine the average of each
variable. I constrained the range of height and weight to prevent the use of questionable data. The
maximum value of height is three meters and of weight is 500 kg.
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Chapter 3.1.2.3: The Algorithm to Distinguish T2DM and Non-T2DM Patients
Before building the temporal representation, I built an algorithm to differentiate T2DM patients
and non-T2DM patients. The T2DM patients should satisfy one of the three criteria 1) a T2DM
diagnosis codes; 2) use of T2DM medications except for metformin, or 3) using metformin
combined with a record of abnormal plasma glucose. Non-T2DM patients should meet the
following three criteria 1) patients without any DM and DM-related diagnosis codes; 2) patients
without DM medications; and 3) patients without records of abnormal plasma glucose. The criteria
for glucose measurement followed the ADA guide. Both T2DM and non-T2DM patients should
not receive any T1DM diagnosis codes. Detail of the diabetes criteria is listed in Table 7.

Table 7. The data element of diabetes criteria
DM Dx
and DM
related Dx
DM meds

Criteria of
glucose
measurement

Data Element of Diabetes Criteria
T1DM Diagnosis Codes: 250.x1,250.x3
T2DM Diagnosis Codes: 250.x0,250.x2
DM related Diagnosis Codes: 277.7,648.0x,648.8x,791.5,790.2,790.29,790.21,790.22
T1DM Medications:
Insulin, pramlintide, symlin
T2DM Medications:
acetohexamide, tolazamide, chlorpropamide, glipizide, gluburide, glimepiride,
repaglinide, nateglinide, metformin, rosiglitazone, pioglitazone, troglitazone, acarbose,
miglitol, sitagliptin, exenatide, dymelor,tolinase, diabinese, Glucotrol, Glucotrol- XL,
micronase, glynase, diabeta,amaryl, prandin,starlix, Glucophage, Avandia, ACTOS,
rezulin, precise, glyset, Januvia, byetta
T2DM
Non-T2DM
HbA1c>6.5%
HbA1c<5.6%
FPG>=126mg/dL
FPG>=126mg/dL
2hPG>=200mg/dL
2Hpg<140mg/dL
RPG>200mg/dL
RPG<=110mg/dL

Chapter 3.1.2.4: Introduction of Each Types of Temporal Representation
When we spread patient data into the timeline, the data points of a patient's data are not evenly
distributed. Besides, when the data points are closer to the date of diagnosis, the data points might
be more important than the ones further from the date of diagnosis. Based on this assumption, this
research set up three types of temporal representation. A simple illustration of three types of
temporal representation is shown in Figure 4. In the figure, the non-temporal representation uses
the latest time point, which indicates the nearest information of a feature related to the event. An
interval-temporal representation utilizes the full information but aggregates the information into
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each interval. The continuous-temporal representation utilizes not only the full information but
also the trend presenting in the dataset.
Figure 4. The Illustration of Three Types of Temporal Representations

The table 8 is an example of a non-temporal representation. In the non-temporal representation,
each row is a patient, and each column is a feature of a patient. The value of each cell is the latest
information about this feature of a patient. The drawbacks of non-temporal representation are that
EHR data might be spotty and inconsistent and lack the concept of time. For example, the diagnosis
of hypertension was one month ago, and the diagnosis of influenza was one year ago. Were both
events equally crucial for the prognostic prediction model?
Table 8.The example of Non-Temporal Representation
Patient

401.1

Prozac

HDL

Systolic

Class

A
B
C
D
E

Y
N
N
Y
Y

Y
N
Y
Y
N

30
40
44
45
20

140
110
145
130
130

T2DM
Non-T2DM
T2DM
Non-T2DM
T2DM

Interval-temporal representation divides the complete information into several equal-length
periods like one month, two months, one year, two years, and others. Table 9 is the example of
interval-temporal representation. The interval-temporal representation can be considered an
extension of non-temporal representation but can incorporate some concepts of time. Compared
with non-temporal representation, interval representation can use more columns to represent the
same variables at different time points. One of the drawbacks of this kind of representation is too
much granularity. The curse of dimensions, a situation with too many variables but without enough
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examples, can occur with interval representation. The curse of dimensions affects the performance
of machine learning algorithms. Another drawback is missing values. Unlike non-temporal
representation, the interval-temporal representation will present several time-points, some lacking
information. Although the curse of dimensions remains a challenge, we can use feature selection
to reduce irrelevant variables to avoid the curse of dimensions. For missing values, I can use
imputation to mitigate the effects of this problem. The most important question is whether interval
representation lacks information about the order of events. This means that machine learning
cannot discern which event happened first and which event happened next. This challenge,
however, cannot be solved by interval representation. I propose to develop continuous
representation to compensate for this deficit.
Table 9. The example of Interval-Temporal Representation
Patient

A
B
C
D
E

Month 1
401.1
Prozac

HDL

Systolic

Month 2
401.1
Prozac

HDL

Systolic

Y
N
N
N
Y

30
50
30
42
25

120
110
120
140
120

Y
N
N
Y
N

30
40
44
45
20

140
110
145
130
130

Y
N
N
Y
N

Y
N
Y
N
N

Class

T2DM
Non-T2DM
T2DM
Non-T2DM
T2DM

Compared to interval-temporal representation, which treats every event on a timeline discretely,
continuous-temporal representation treats every variable including diagnosis, medications, lab
results, and vital signs continuously in the timeline. The continuous-temporal representation is a
regression function that can predict future points continuously based on currently available data
points (Figure 5). Those predicted future data points are expected to improve the performance of
the prognostic prediction model. Continuous-temporal representation is the best temporal
representation and can be generalized to other types of chronic conditions. The continuoustemporal representation, however, has several disadvantages including unknown methods to
accurately estimate variables, mitigate confounder effects, and demonstrate previous data points
useful for predicting the future.

34

Figure 5. The Illustration of Continuous-Temporal Representation

The previously mentioned disadvantages of continuous-temporal representation can be solved with
deep learning. Deep learning is a linear algebra-based machine-learning method that can
incorporate categorical and numerical data to generate a vector for further learning. Based on this,
the continuous-temporal representation will use deep-learning methods to achieve such as RNN.
Chapter 3.1.2.5: The Experimental Schemes
There are two experimental designs in this research. The first is the cutting-points scheme, and the
second is the random-split scheme. The cutting-points scheme is illustrated in Figure 6. In the
figure, the blue part is the data we used to build the prediction model, and the red part is the data
discarded for developing a time gap. If we want to predict four different time points, we need to
build four models.
Figure 6. The Illustration of Cutting Points Scheme
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Figure 7. The Illustration of the limitation of Cutting Points Scheme
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There are several limitations for this experiment design. The primary limitation is an inconsistent
number of patients. There were fewer patients for building earlier identification models. The
estimated risks of cutting design models are decreasing and variations are increasing. The detail is
presented in Figure 7.
In long-term estimation for a chronic condition, this is a problem for building a prevention plan.
The other problem is data sparsity, which might affect the results of outputs. This is why we need
another training design, called the “random-split design.” The random-split scheme (Figure 8) is
unlike the cutting-point design, which is forced to use data before specific time points. The random
design splits patient data into a portion for building models (the blue part) and a piece for creating
a time gap (the red part). This design, combined with a deep learning model, can make some
projections (dashed line) in the future even though we do not have data after specific time points.
Figure 8. The Illustration of the Random Splits Scheme

In this research, non-temporal representations and interval-temporal representations used both
cutting points, and deep learning used random-split designs.
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Paris, France
January 19, 2015
Abstract
We analyze the stochastic average gradient (SAG) method for optimizing the sum of a finite
number of smooth convex functions. Like stochastic gradient (SG) methods, the SAG method’s
cost is independent
of the
number of
terms in the sum. However, by incorporating a
Chapter 3.1.2.6: iteration
Introduction
of Machine
Learning
Methods
memory of previous gradient values the SAG method achieves a faster
p convergence rate than
black-box SG methods. The convergence rate is improved from O(1/ k) to O(1/k) in general,
Several machine learning
were used to the
evaluate
the performance
of the
types of
and when algorithms
the sum is strongly-convex
convergence
rate is improved
fromthree
the sub-linear
O(1/k) to a linear convergence rate of the form O(⇢k ) for ⇢ < 1. Further, in many cases the
temporal representations.
Inrate
theofevaluation
of non-temporal
representations
and interval-temporal
convergence
the new method
is also faster than
black-box deterministic
gradient methods,
in terms of the number of gradient evaluations. This extends our earlier work [Le Roux et al.,
representations, several
different
types
machine
algorithms—including
linearNumerical
models,
2012], which
only lead
to aof
faster
rate forlearning
well-conditioned
strongly-convex problems.
experiments indicate that the new algorithm often dramatically outperforms existing SG and
ensemble methods,
support vector machine, decision trees, multiple layer perceptions, and
deterministic gradient methods, and that the performance may be further improved through
the use of non-uniform sampling strategies.

Bayesian methods—were applied to this research.

This research primarily tested logistic

regression, Lasso, Elastic Net, and multi-task linear models. Ensemble methods encompassed

1

Introduction

random forest and AdaBoost. The equation of each algorithm will be listed in Table 10. AUC,
A plethora
the optimization
problems
arising
practice involve
computing
a minimizer
precision, recall,
and F1ofmeasure
are applied
to evaluate
theinperformance
of each
machine
learning of a
finite sum of functions measuring misfit over a large number of data points. A classical example is

algorithm. least-squares regression,

n
1X

minimize
(aT x bi )2 ,
Assuming s ≥ 0, Chebychev’s
inequality
x2Rp
n i=1 i gives
Table 10. The Equation forp Each Machine Learning Algorithm

where the ai 2 R and bi 2 R are the data samples associated
with a regression problem. Another
2
PE*
≤
var(mr)/s
(4)
important example is logistic
regression,
Algorithm

Methods
n
X
Logistic Regression
1for
A more revealing expression
the
variance
mr is derived in the following:
minimize
log(1
+ exp( biof
a>
i x)),
x2Rp
n
Let
i=1
where the ai 2 Rp and bi 2 { 1, 1} are the data samples associated with a binary classification
Random forest
ĵ (X,Yin)=arg
max
problem. A key challenge arising
modern
applications
is that the j)
number of data points n
j≠Y PΘ (h(X,Θ)=
(also known as training examples) can be extremely large, while there is often a large amount of
between examples. The most wildly successful class of algorithms for taking advantage of
AdaBoost redundancy
so

Support vector machine

1

mr(X,Y ) = PΘ (h(X,Θ)=Y )− PΘ (h(X,Θ)= ĵ (X,Y ))
= EΘ [ I(h(X,Θ)=Y )− I(h(X,Θ)= ĵ (X,Y ))] .

The continuous-temporal
representation
used Recurrent
Network (RNN) as a machine
Definition
2.2 The raw margin
function Neural
is
learning method to learn the progress of patient history. RNN can process the information within
rmg(Θ,X,Y )= I(h(X,Θ)=Y )− I(h(X,Θ)= ĵ (X,Y )) .
a period or information of a single visit as a stage and transfer the information from this stage to
the next step. RNN also outputs the outcome of each stage for further prediction. The process is
Thus, mr(X,Y) is the expectation of rmg(Θ,X,Y) with respect to Θ . For any
found in Figures function
9 and 10. f the identity

[EΘ f (Θ)]2 = EΘ,Θ' f (Θ) f (Θ' )
holds where Θ,Θ' are independent with the same distribution, implying that

mr(X,Y )2 = EΘ,Θ' rmg(Θ,X,Y )rmg(Θ' ,X,Y )
Using (5) gives
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var(mr)=EΘ,Θ' (covX,Y rmg(Θ,X,Y )rmg(Θ' ,X,Y ))

(5)

Figure 9. The Illustration of the Recurrent Neural Network

Figure 10. The Illustration of the LSTM cell and GRU Cell

Each unit of RNN used to process information is called a cell. There are two major types of cells.
One is called an LSTM cell and the other is a GRU cell. The equation and process of LSTM and
GRU cells are the following. The LSTM cell had three gates and two states. The three gates are
the input gate, output gate, and forget gate. The forget gate determines how much information from
the previous stage should be discarded, the input gate updates the newest information, and the
output gate sends the information to the next LSTM cell. There are two states of the LSTM cell;
one is the cell state and the other is the hidden state. The cell state is across the whole LSTM-RNN,
and the hidden state is just within each LSTM cell and transfers to the next LSTM cell. The cell
state can be considered a long-term memory, and the hidden state can be seen as short-term
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memory. The GRU cell combined the input gate and the forget gate together to form an update
gate. Besides, the cell state combines with the hidden state to be simplified as a hidden state. Thus,
GRU cell is not like an LSTM cell, which has long-term and short-term memory. The equation of
LSTM cell and GRU cell is listed in Table 11.
Table 11. The illustration of the equation of LSTM cell and GRU cell

RNN has the advantage of utilizing the previous information for estimating the current risks of
disease. The limitation is that RNN needs current information combined with previous information
to estimate present risks. In clinical reality, we not only need current risks but also need to project
future risks, especially for prevention.
To overcome this limitation, the seq2seq model was proposed. The seq2seq model originally was
applied to machine translation, which learned from the information in the encoder then
continuously generated outputs with no data inputs. This research used this advantage to combine
random splits to generate a sequential risk estimation for each patient. The illustration is found in
Figure 11.
Figure 11. The Illustration of the seq2seq Model
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Chapter 3.1.3: Findings
In this section, I will summarize the finding of the UTP dataset, the performance of the
conventional model, non-temporal representation, interval-temporal representation, and
continuous-temporal representation.

Chapter 3.1.3.1: The Summary of the UTP dataset
In Table 12, I compare the following variables that might affect the performance. For T2DM and
non-T2DM patients, there were no differences between enrolling years, gender, and systolic and
diastolic pressure. The only differences were in age and weight. The T2DM patients were more
elderly and weighed more.
Table 12. The Summary of UTP Dataset
UT Physician
Enrolling years
Enrolling age
Gender Ratio
Weight
Systolic
Diastolic

T2DM (Mean/ S.D.)
4.423/5.759 year
56.13/16.11 year
Female: 57.8 % /Male: 42.2%
90.2/27.4 Kg
131.23/20.0 mmHg
78.7/11.6 mmHg

Non-T2DM (Mean/ S.D.)
5.683/2.674 year
44.35/20.79 year
Female: 59.7 % /Male: 40.3%
59.8/33.7 Kg
122.83/23.3 mmHg
74.7 /15.1 mmHg

Chapter 3.1.3.2: The Summary of Top Variables over Different Data Types
In the previous section, I introduced some differences that might affect the performance of the
prediction model. For more detail, I present the difference between T2DM and non-T2DM patients
in the UTP dataset. In this section, I will present the differences in the diagnoses, medications,
labs, chronic conditions, and vital signs. The T2DM patients received more diagnoses in
unspecified essential hypertension, shortness of breath, pulmonary collapse, chest pain, abnormal
pain, conduction disorder or cardiac dysrhythmia, and asthma. Sleep disorder and osteoporosis had
a few more T2DM patients than non-T2DM patients. A more interesting phenomenon is that nonT2DM patients generally had more records of labs and vital signs than T2DM patients.
The essential information such as BMI, systolic blood pressure, diastolic blood pressure is not
complete for everyone. The information, generally speaking, was the essential factor in most of
the prediction models. This might introduce some strong limitations in applying those prediction
models to the EHR system.
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In addition, there were no differences among the drugs that were prescribed to T2DM and nonT2DM patients. All high-frequency drugs were aspirin. This situation might be due to UTP being
a primary care hospital. As such, all relevant information is in Figure 12.
Figure 12. The Summary of Top Information Rich Variables - UTP
Class
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Chapter 3.1.3.3: The Conventional Model Performance – UTP
For testing the performance of three types of proposed temporal representations, the conventional
model proposed a baseline for comparison. The conventional model is based on the traditional
variables for predicting Type 2 diabetes. Those variables include BMI, systolic blood pressure,
diastolic blood pressure, triglycerides, fasting plasma glucose, HbA1c, records of hypertension,
records of hyperlipidemia, records of obesity, age, gender, and race. Age was recorded by
comparing the date of birth to the last time point information was recorded for the patient. The
absence or presence of hypertension, hyperlipidemia, and obesity of a patient was based on CCI
and constituted binary variables. Other patient variables came from the last records of those
variables. If a patient did not have variables recorded, I put the average value of the variable. Under
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the same comparing test scheme, this section and the next section used the cutting-points scheme.
Table 13 presented the T2DM and non-T2DM patients at each time point.
In Figure 13, I listed all the variables that show the percentage of patients with values at that time
point. More than sixty percent of patients had a record of systolic and diastolic blood pressure, and
the percentage decreased over the years. The BMI decreased more sharply, which is the most
important variable to estimate the risks of developing T2DM. Other variables stayed constant over
the years.
Table 13. The Summary of Patient Number at Cutting Points Scheme-UTP
Cutting time points

T2DM

Non-T2DM

One year
Two years
Three years
Four years
Five years

5,232
4,049
3,232
2,637
2,117

83,710
64,565
49,892
40,297
32,856

In the figure 13, I listed the all variables which how many percent of patients with values at that
time point. More than sixty percent patients had record of systolic and diastolic blood pressure and
the percentage decreased over years. The BMI decreased more sharply which is the most important
variable to estimate the risks of developing T2DM. Other variables stayed constant over years.
Figure 13. The Proportion of Patients with Records Over Years in Conventional ModelUTP
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In Table 14, I listed the performance of the conventional model at each time point. The
performance is consistent at AUC 0.5, which means the model randomly predicted the outcome of
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each patient. With the current available data, the results implied that the conventional model cannot
provide any reliable information to estimate future risks.
Table 14. The Performance of Conventional Model at Cutting Points Scheme-UTP
Cutting time points

AUC

ACC

One year
Two years
Three years
Four years
Five years

0.481
0.517
0.494
0.482
0.519

0.580
0.553
0.547
0.497
0.534

Chapter 3.1.3.4: Non-temporal and Temporal Representations Performance – UTP
In the following section, I presented the performance of three types of temporal representation. In
Figure 14, the model used all available information before the cutting timepoints and tested the
non-temporal representation. The earlier cutting timepoint indicates less information for building
a prediction model and presented a poor performance. In all the testing of machine learning
algorithms, the top three machine learning algorithms with the best results were random forest,
perceptron, and logistic regression. For interval-temporal representation, the top three machine
learning algorithms were logistic regression, perceptron, and random forest (Figure 15).
Figure 14. The Results of Non-Temporal Representation – UTP
The performance of Non-Temporal Representation over different Machine learning Algorithms
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Ridge

Figure 15. The Results of Interval-Temporal Representation - UTP
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Chapter 3.1.3.5: Random Split Model Performance – UTP
In this part, I will introduce the performance of the random split scheme. The first part is the basic
information for the experiment performed under the random split scheme. In Table 15, we found
the number of case-control in the full dataset and above three years of data in the encoder, which
represents the more comprehensive information in the training dataset.
Table 15. The Basic Information of Random Split Scheme - UTP
UTP Dataset
Case Number
Years in
Years in
(All Patients)
Encoder
Decoder
(Mean/S.D.)
(Mean/S.D.)
years
Years
Non-T2DM
85,960
(3.32 /2.81)
(3.32/2.82)
T2DM
5,954
(3.03/2.45)
(3.12/2.51)
UTP Dataset
Case Number
Years in
Years in
(Patients at
Encoder
Decoder
Least with
(Mean/S.D.)
(Mean/S.D.)
Three Years of
years
Years
History in
Encoder)
Non-T2DM
40,017
(5.61 /2.61)
(3.58/2.60)
T2DM
2,684
(5.13/2.24)
(3.16/2.28)

Ages
(Mean/S.D.)
(40.0/23.9)
(54.9/16.5)
Ages
(Mean/S.D.)

(40/23.9)
(55.0/16.3)

In Table 16, I listed the performance of non-temporal representation and the performance of
Random Split by using all patients and using patients with at least three years of data in the encoder.
The performance was better when using the patients with more years of information in the encoder
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than using patients with fewer years of information in the encoder. The attention mechanism
seemed to have no effect on the performance in our experiment.
Table 16. The Performance of Random Split Scheme - UTP
Table 16.A: Non-Temporal UTP
Method
Logistic Regression
Random Forest

AUC
0.648
0.639

Table 16.B: Random Split UTP_all
Method
RETAIN
RNN
seq2seq
seq2seq with attention wrapper in
encoder
seq2seq with attention wrapper in
decoder

AUC
0.718
0.704
0.823
0.823
0.805

Table 16.C: Random Split UTP_Encoder over Three Years
Method
AUC
RETAIN
0.732
RNN
0.720
seq2seq
0.831
seq2seq with attention wrapper in
0.830
encoder
seq2seq with attention wrapper in
0.821
decoder
Table 17 uses Mean Absolute Error (MAE )to estimate the performance of early detection of
T2DM. From this perspective, the MAE of T2DM patients should be much higher than that of
non-T2DM patients. The results met my expectations but using patients with more information in
the encoder did not improve the performance. Thus, the attention mechanism makes no difference
in the performance of early detection of T2DM.
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Table 17. The MAE of Random Split Scheme - UTP
Model

MAE (T2DM group)
Continuous: UTP_all
0.278
0.283

MAE (Non-T2DM group)

seq2seq
0.052
seq2seq with attention
0.074
wrapper in encoder
seq2seq with attention
0.281
0.07
wrapper in decoder
Continuous: UTP_encoder_year over three years
seq2seq
0.280
0.051
seq2seq with attention
0.284
0.073
wrapper in encoder
seq2seq with attention
0.282
0.071
wrapper in decoder

Chapter 3.2: Running the Three Approaches on CHF Dataset
Chapter 3.2.0: Introduction
The Cerner Health Facts database is a real-world, de-identified, HIPAA-compliant electronic
health records (EHR) database. The data in this database represents the care delivered by
participating Cerner client hospitals and clinics that agreed to share the data for research purposes.
All identifiable patient health information was removed from the database to accelerate the
research. The Cerner Health Facts (CHF) is a comprehensive dataset, unlike claims data, which
primarily covers billing data. The CHF dataset provides complete details such as encounter facts,
diagnosis facts, procedure facts, medication facts, laboratory facts, microbiology facts, and other
information. Each Patient in the CHF dataset has a unique identifier. The unique identifier is the
identifier that can track a patient over different hospitals or insurance programs. For this research,
I used the Cerner 2015 dataset, which enrolled 49,826,219 unique patients with 2.7 billion clinical
events from 2000 to 2015. Six hundred fifteen (615) hospitals were represented in this dataset. In
order to achieve the goal of this research, I used patients who had at least five years of records.
The inclusion criteria identified 2,129,885 patients. After the data-cleaning process, there were
1,401,676 patients still in this research. There were 1,247,541 non-T2DM patients, and 154,135
were T2DM patients.
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Chapter 3.2.1: The Demographic Information of CHF Datasets
The following sections will illustrate the demographic constitution, the frequency of diagnosis,
medications, laboratory work, and vital signs. This section will also provide the proportion of
missing values of some essential measurements such as height, weight, and blood pressure in both
datasets. The first section includes a summary of demographic information regarding the two data
sets. The demographic information includes race, gender, and age when enrolled in this dataset.
Figure 16 . The Summary of Demographic Features - CHF

Fig. 16A is the race proportion of CHF’ dataset; the figure excluded race below 1% of the dataset.
Fig. 16B is the gender proportion of CHF’ dataset; the figure excluded gender below 1% of the
dataset. Fig. 16C is the age proportion of CHF’s dataset.
3.1.2.2: The Information of Years of Data of CHF
From Figure 17, the patient with years of data sees a drop over the years. More than half of the
patients had data from within the past five years in the CHF dataset.
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Figure 17. The Summary of Proportion of Patient with Datum Over Years - CHF
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Chapter 3.2.2: Methods
The methods of validation used included three types of temporal representations as well as the
UTP dataset. Please refer to all methods in Chapter 3.1.2.
Chapter 3.2.3: Findings
Chapter 3.2.3.1: The Summary of the CHF dataset
In this table, we can find the T2DM patients in CHF’s dataset with shorter enrolled years. T2DM
patients will still be elderly and higher weight than non-T2DM patients. The records of blood
pressure showed no significant difference between T2DM and non-T2DM patients.
Table 18. The Summary of CHF Dataset
Cerner Health Facts
Enrolling year
Enrolling age
Gender Ratio
Weight
Systolic
Diastolic

T2DM (Mean/ S.D.)
4.478/5.754 year
57.23/16.11 year
Female: 68.1 % /Male: 31.9%
88.13/31.66 Kg
127.83/24.25 mmHg
70.38/14.75 mmHg

Non-T2DM (Mean/ S.D.)
5.675/2.627 year
44.35/23.79 year
Female: 61.2 % /Male: 38.8%
69.58/32.37 Kg
122.04 /22.41 mmHg
69.90 /14.75 mmHg

Chapter 3.2.3.2: The Summary of Top Variables over Different Data Types – CHF
In the previous section, I introduced some differences which might affect the performance of the
prediction model, for more detail presenting the differences between the T2DM and non-T2DM
patients in the CHF dataset. In this section, I will present the differences in diagnosis, medications,
lab, chronic conditions, and vital signs. The T2DM patients received fewer diagnoses in
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unspecified essential hypertension and unspecified hyperlipidemia. There was no significant
difference in diagnoses of malaise and other fatigue, long-term records of medication, and
abnormal pain between T2DM and non-T2DM.
The information, generally speaking, was the essential factor in most prediction models. The
records of several basic and regular measurements of EHR were missing such as weight, systolic
blood pressure, diastolic blood pressure, and height. This might introduce some strong limitations
in applying those prediction models to the EHR system.
All relevant information in this regard is in Figure 18.
Figure 18 . The Summary of Top Information Rich Variables - CHF
Class
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Chapter 3.2.3.3: The Conventional Model Performance – CHF
All settings and variables in the conventional model of CHF were as good as the UTP dataset. In
Table 19, the number of T2DM and non-T2DM patients in the CHF at different time points is
listed.

49

Table 19 . The Summary of Patient Number at Cutting Points Scheme-CHF
Cutting time points

T2DM

Non-T2DM

One year
Two years
Three years
Four years
Five years

153,269
152,616
113,551
80,508
52,881

1,243,395
1,241,222
1,178,534
1,084,310
835,030

Based on figure 19, the pattern of patients with records of selected variables is similar to the UTP
dataset. The conventional model performance is as weak as the UTP dataset (Table 20). This
implies that the bigger dataset with poor data quality still cannot improve performance. It also
implies that we should use other methods to overcome the limitations.
Figure 19. The Proportion of Patients with Records of Variables Over Years in
Conventional Model-CHF
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Table 20. The Performance of Conventional Model at Cutting Points Scheme-CHF
Cutting time points

AUC

ACC

One year
Two years
Three years
Four years
Five years

0.497
0.497
0.498
0.501
0.499

0.448
0.524
0.526
0.502
0.19
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Chapter 3.2.3.4: Non-temporal and Temporal Representations Performance – CHF
From the results of non-temporal and interval-temporal representations of CHF, the performance
was better than the performance of UTP, but it was limited. In all the testing of the machine
learning algorithms, logistic regression was still the best in both non-temporal (Figure 20) and
interval-temporal representation (Figure 21). The next two machine learning algorithms were
random forest and support vector machine. In continuous-temporal representation, I used the RNN
as the testing algorithm. The performance of continuous-temporal representation was much better
than non-temporal and interval-temporal representation (Figure 22). If the model used the larger
dataset, the performance was improved in a limited way.
Figure 20. The results of Non-Temporal Representation - CHF

The performance of Non-Temporal Representation over different Machine learning Algorithms

0.70

AUC

0.65

0.60

0.55

1

2

3

4

5

Year before the end of date
method

AdaBoost

DecisionTree

LinearSVC

LR

RandomForest

Figure 21. The results of Interval-Temporal Representation - CHF
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Figure 22. The Results of Continuous-Temporal Representation - UTP & CHF
The performance of Continuous-Temporal Representation under simple RNN
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Chapter 3.2.3.5: Random Split Model Performance – CHF
Table 21includes the average year of data in the encoder and decoder and the age in the CHF
dataset. However, in the all patients dataset, the T2DM patients had shorter years of data in both
the encoder and decoder.
Table 21.The Basic Information of Random Split Scheme - CHF
Cerner Dataset
(All Patients)

Case Number

Non-T2DM
T2DM
Cerner Dataset
(Patients at
Least with
Three Years of
History in
Encoder)
Non-T2DM
T2DM

1,221,979
150,075
Case Number

437,722
30,780

Years in
Encoder
(Mean/S.D.)
years
(2.10 /1.91)
(1.45/1.64)
Years in
Encoder
(Mean/S.D.)
years

Years in
Decoder
(Mean/S.D.)
years
(3.07/1.90)
(2.43/1.61)
Years in
Decoder
(Mean/S.D.)
years

Ages
(Mean/S.D.)

(4.22 /1.43)
(4.11/1.43)

(2.21/1.42)
(2.06/1.34)

(44.4/23.3)
(56.3/15.3)
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(44.5/23.8)
(57.6/15.3)
Ages
(Mean/S.D.)

Figure 23.The Outputs of the seq2seq Model

Figure 23 presented the outputs of the seq2seq model of T2DM and non-T2DM patients. For
T2DM patients, the outputs of the model fulfill our original design. There was some noise in the
projection part (dashed line) of non-T2DM patients. In Figure 23, both points have meaning. For
T2DM patients, the point indicated the time point of the receiving T2DM diagnosis, and for nonT2DM patients, it represented the time point of the last visit. The solid line indicated knowledge
of the health condition of the patient and the dashed line represented lack of knowledge about the
health condition.
In Table 16, I listed the performance of non-temporal representation, the performance of random
split using all patients and those with at least three years of data in the encoder. By using the
patients with more years of information in the encoder, the performance was better than using
patients with fewer years of information in the encoder. It seems that the attention mechanism did
not improve the performance of our experiment.
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Table 22. The Performance of Random Split Scheme - CHF
Table 22.A: Random Split CHF_all
Method
RNN
Retain
Seq2seq
Seq2seq (encoder attention)
Seq2seq (decoder attention)

AUC
0.796
0.796
0.894
0.884
0.898

Table 22.B: Random Split CHF_all_Encoder_ over Three Years
Method
AUC
RNN
0.810
Retain
0.810
Seq2seq
0.920
Seq2seq (encoder attention)
0.917
Seq2seq (decoder attention)
0.918
In Table 22, I listed the performance of non-temporal representation, the performance of random
split using all patients and those with at least three years of data in the encoder. By using the
patients with more years of information in the encoder, the performance was better than using
patients with fewer years of information in the encoder. It seems that the attention mechanism did
not improve the performance of our experiment.
Table 23. The MAE of Random Split Scheme - CHF
Continuous: Cerner_all
0.294
0.298

Seq2seq
0.069
Seq2seq with attention
0.075
wrapper in encoder
Seq2seq with attention
0.293
0.072
wrapper in decoder
Continuous: Cerner_ encoder_year over three years
Seq2seq
0.310
0.072
Seq2seq with attention
0.312
0.077
wrapper in encoder
Seq2seq with attention
0.313
0.074
wrapper in decoder
In Table 23, I used MAE to estimate the performance of early detection of T2DM. From this
perspective, the MAE of T2DM patients should be much higher than that of non-T2DM patients.
The results met my expectations but using patients with more information in the encoder did not
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improve the performance. Thus, the attention mechanism makes no difference in the performance
of the early detection of T2DM.
Figure 24. TimeROC of UTP and CHF

Figure 24 represents two settings. The first setting is using the patients who had at least two years
of data with at least one year in the encoder and at least one year in the decoder. The second setting
is patients who had more than three years of data in the encoder. The results in the UTP dataset
indicated that the seq2seq model with the decoder attention mechanism had the best performance.
The performance of seq2seq without the attention mechanism was next, and the third was the
seq2seq model with encoder attention. The results in the CHF presented the same trend but had
some noise.

Chapter 3.3: Discussion and Comparison
Chapter 3.3.1: The Comparison of Demographic Information Between Two Datasets
Based on the demographic information from these two datasets, there were some differences
between the two datasets. The first is that CHF had a higher proportion of Caucasian people
compared with the UTP dataset. In addition, CHF had more patients whose age when entering this
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dataset was over 65. More interesting is that the UTP dataset had more other races compared with
the CHF dataset. Both datasets had more female patients than male patients.
Chapter 3.3.2: The Comparison of Patient with Datum Over Years Between Two Datasets
Comparing UTP and CHF, the patients in the CHF dataset had more years of data than the UTP
dataset. Whether the information is useful for developing a T2DM prediction model requires
further examination.
Chapter 3.3.2: The Comparison of Patients Detail Between Two Datasets
For comparing T2DM and non-T2DM groups, I chose the top ten variables which most patients
have. From those variables, we can build general information about the two datasets from
diagnosis and medications to labs and vitals. From the perspective of diagnosis, under the local
level, T2DM patients received more diagnoses of hypertension, chest pain, abdominal pain, and
shortness of breath. At the national level, T2DM patients suffered not only hypertension but also
hyperlipidemia. Additionally, T2DM patients had more records of long-term medication usage. In
the records on medications, in the UTP dataset, most prescriptions were aspirin because UTP is
the local primary care hospital. CHF, on the other hand, presented a more diverse phenomenon:
more prescriptions, such as nonsteroidal anti-inflammatory drugs (NASID) and some opioid drugs,
including fentanyl and morphine. In chronic conditions, UTP data presented T2DM patients with
more chronic diseases, such as asthma, conduction disorder, cardiac dysrhythmia, and
hypertension. The CHF dataset only showed that T2DM patients had more records of hypertension
and hyperlipidemia. In datasets of records of labs and vitals, more (half of) non-T2DM patients
received a complete blood count test as well as T2DM patients. In a good practice, those basic
vital signs were measured and documented in the EHRs. These records may have been paper-based
and were not recorded into EHR. The more interesting part is the high proportion of the missing
value of weight and height. This phenomenon might corrupt the performance of the general model
for detecting T2DM patients using a conventional model.
Chapter 3.3.3: The Discussion Between Two Datasets
A. The Possible Explanation of the Performance
Based on Figures 14, 15, 20, and 21, the interval-temporal representation improves a limited
performance compared with the non-temporal representation. This implies that the information for
building a prediction model is insufficient or irrelevant to the target I chose, which means I did not
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have enough information to make a prediction. This explanation can be supported by the UTP,
single medical center, which presented a worse performance compared with the CHF (multiple
centers) dataset. Having enough information does not mean having more records but means having
high-quality information. The high-quality information comes from well-managed data that can
track what information should be collected and be documented. Unfortunately, both datasets did
not qualify for the definition, as they had irrelevant information and corrupted the performance of
the prediction model. For example, whether the patient came to a vaccine check is irrelevant to
this research prediction model.
Deep learning provides an alternative way to overcome limitations such as insufficient or irrelevant
information and achieve an acceptable performance (Figure 22). However, deep learning is a more
data-driven method that can be highly affected by the data we put in. The other problem is that
deep learning cannot provide a constant and reliable explanation for why the outcome should be
as the model predicts.
B. The Solution and Explanation of the Continuous Outputs by the seq2seq Model
In Figure 23, I demonstrated the seq2seq model that combines the random split scheme to
overcome the limitation mentioned in the previous section. The outputs, generally speaking, are
reasonable but still have some problems. The first issue is the noise that increases sharply and then
drops down quickly in the non-T2DM patients. The noise happens in the projection part, where
the model estimates the possibility of an unknown future for a given non-T2DM patient. As
previously mentioned (Figure 10), a random split scheme randomly separates a patient's
information into an encoder and decoder, and seq2seq outputs a sequence that represents a
possibility of each point of a fixed period (e.g., the annual possibility of developing T2DM in the
next ten years). This condition implies that, after a specific time point, the patient has no further
information, especially the non-T2DM patient. For the no further information part, I called this the
projection part. In the projection part, the seq2seq model still needs supervised labels. For T2DM
patients, the labels represent T2DM, and non-T2DM patients represent non-T2DM. This is still a
challenge, and I can try other newly developed seq2seq models or other deep learning methods,
such as a drop out mechanism which removes the connections[178] or the neurons[179] or freezing
the weight[180].
On the other side, I can go back to what happened in the encoder, which is the information
processor extracting and generating the representation from the decoder to the project. As we all
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know, EHRs are a complex dataset and incorporate a lot of bias. The deep-learning model has been
proven as a way to handle the complex dataset. In this research, I used a simple RNN and attention
mechanism in the encoder or decoder, which assists the model in extracting essential information
to build the final state for the decoder to project. As the results in Table 19 show, simple RNN
outcompetes the performance while using an attention mechanism. From the result, I cannot
conclude the attention mechanism is not useful because I did not try all attention mechanisms.
However, we need to check some experiment design problems. I aggregated the information
annually and entered the dataset to the patients’ final date in the dataset. This design can hold realtime information among medical events. I did not create the order of each event in each period,
through which some medical information could be inferred (e.g., Hba1c before the T2DM
diagnosis). I can apply a shorter period for each patient but also introduce more zero values. Based
on the previous study, the permutation of the order of a patient’s history did not change the
performance of the model, but adding or deleting patient history alters model performance [181].
The result implies that we might change the order of healthcare events within the period and train
pre-embedding for reducing the noise. Another study also pointed out that acute conditions tend
to offer fewer opportunities to be predictable because of their spontaneous occurrences[182].
Removing the acute conditions might be an alternative solution.
My model treats the information in the EHRs, such as diagnosis, medications, or lab results, as a
word in a sentence or in a paragraph, which is the full information of a given patient. The context
of that information is not as strong as the real text documents. Patients might receive a diagnosis
first and then another diagnosis later. For clinicians, both diagnoses might not have temporal
correlations but may have just happened recently. The attention mechanism might highlight them
as important information. If the dataset had more information, those false temporal correlations
might also increase. This correlation corrupts the whole performance. This explanation can be
supported by Figure 24.
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Chapter 4: Identifying the pattern or algorithms to early identify
T2DM patients
Chapter 4.0: Overview
In Chapter 3, this dissertation explored the performance of different types of temporal
representations combined with different kinds of machine learning algorithms. In this chapter, this
dissertation wants to explore some possible patterns which can develop early identification
solutions to prevent T2DM. In the beginning, I will introduce some methods used to explore the
original dataset. Then, I will examine the variables identified by the machine learning algorithms.
Finally, I will discuss the limitation of current machine learning algorithms on EMR/EHR research.

Chapter 4.1: Examination of The Original Datasets
Chapter 4.1.0: Introduction
Because T2DM is a chronic disease that needs a long time to develop, this implies that chronic
conditions contribute more to developing T2DM. Others, like long-term medication use, is another
aspect worthy of consideration. The limitation in this research is we only have the date of
prescriptions and estimation of refill times, but we lack other information from the pharmacy
which can indicate when and what types of drug this patient received. Lab and vital signs still lack
long-term tracking for patients; this is why I discarded them in this section. For exploring the
chronic conditions, I adopted two types of methods. The first is under the cutting-point scheme,
using biology network to present the interaction among chronic conditions. Then, I used chronic
condition indicators as a variable for using survival analysis to evaluate the relative importance.
Chapter 4.1.1: Methods
Chapter 4.1.1.0: The Biology Network
I also explored the interactions among different chronic conditions between the T2DM group and
the non-T2DM group because some combinations of the chronic conditions might be more
prevalent in T2DM patients than non-T2DM patients. Based on this reason, I profiled the
interactions at each time point of the cutting-point scheme. The greater width of each line indicated
that the interaction between the two variables is more prevalent in the T2DM group than the non-
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T2DM group. The threshold set is three, which means the interaction between two chronic
conditions is three times more frequent in the T2DM group than in the non-T2DM group.

Chapter 4.1.1.1: The Statistical Methods
One of the most significant gaps between clinical research and data-mining fields is extending the
current knowledge based on the findings from the results of the data-mining fields. Considering
T2DM is a chronic condition, most research for developing T2DM prediction models is based on
survival analysis because of time-to-event research. The covariates in this study are the chronic
condition indicators, and we realized the chronic conditions were varied by time. Under this
consideration, I used the Cox proportional time-varying model[184].
A survival analysis must address 1) event, 2) time, and 3) censoring. In this experiment, the event
occurred when this patient was diagnosed with T2DM. Time is the entire observation period of the
patient. In the definition of a survival analysis, censoring is a condition that is partially known in
the research. In this research, the conditions of only non-T2DM patients were known before the
last time of visit. After that time point, I did not know the conditions of those patients. The time
after the last time of visit is called censoring.
There are several limitations of this experimental setting. The covariates of this survival analysis
were chronic condition indicators based on ICD-9-CM. Because of the chronic conditions’ varying
by time, I adapted the Cox time-varying model to handle this problem. Considering T2DM is an
age-associated chronic disease, the survival analysis was performed on all patients in the following
three age groups: 1) age over twenty and below forty, 2) age over forty and below sixty, and 3)
age over sixty.
Chapter 4.1.2: Findings
Chapter 4.1.2.1: The Chronic Condition Indicators Net
In Figure 25 from the upper left, upper right, down left, and down right, representing four different
time points before the end date of the study, coronary atherosclerosis had the most connections
over four time points. When starting from the earliest time point, four years before the end date,
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coronary atherosclerosis still had several contacts with other chronic conditions, including
hypertension, hyperlipidemia, other central and peripheral nervous system disorders, congestive
heart failure, asthma, cardiomyopathy, structural heart disease, and sleep disorders. When
approaching a later time point, coronary atherosclerosis had more connections with other chronic
conditions. The phenomena implied that coronary atherosclerosis might be the most common and
concurrent chronic condition with other chronic diseases.
Figure 25. Chronic Conditions Indicators Net - UTP

When I examined and applied the same threshold to a national-wide dataset, Cerner Health Facts
(Figure 26), the data represented a different pattern. Both chronic pancreatitis and obesity are the
hubs that connect other chronic conditions.
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Figure 26.Chronic Conditions Indicators Net - CHF

Chapter 4.1.2.2: Exploring the High Risk Chronic Conditions from Survival Analysis
The odds ratio of all chronic conditions of patients whose age (above twenty) indicated obesity,
hypertension, and tuberculosis were the top three risk factors of developing T2DM in the UTP
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dataset. Chronic pancreatitis and liver diseases were the next highest risk factors. After stratifying
by age, chronic pancreatitis, gout, and cystic fibrosis were high-risk factors for the patient in group
one. Cystic fibrosis had no statistical significance. Middle-aged patients with tuberculosis or
hypertension had the highest odds ratio of developing T2DM. The third-highest risk factor is liver
function. In more elderly patients, TB, obesity, and chronic pancreatitis were the top three risk
factors.
Figure 27. Results of Cox Time Varying Model - UTP
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Because UTP is a regional primary care clinic, the phenomenon presenting in this dataset may not
be generalized to the national level. To explore the difference between the local and national levels
more accurately, I performed the same analysis on the CHF dataset. The results presented a
different landscape. For adult patients, at the national level, obesity and chronic pancreatitis were
both serious risk factors. The next-highest risk factors were chronic liver disease and chronic renal
failure. TB may have still been a high potential risk factor but lacked any statistical significance,
but when we focused on the younger adults, cystic fibrosis and TB were the most two influential
risk factors with statistical significance. Others were hypertension and obesity. In the middle-aged
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patients, obesity and cystic fibrosis were the top two risk factors. Our results for elderly patients
showed that obesity and chronic pancreatitis were both notable risk factors.
Figure 28. Results of Cox Time Varying Model - CHF
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Chapter 4.1.3: Discussion:
The difference in CCIs between UTP and CHF results in the following findings. Because UTP is
a local primary care center whose patients were transferred to other hospitals, the information is
insufficient. The CHF collected more information on a patient because it is a multiple-center
dataset. However, I need to point out that hospitals joined the CHF system in different years and
that not all hospitals participated. Even though the information is more complete in the CHF dataset,
when a center joined CHF for data sharing still needs to be considered.
The biggest question that previous figures cannot answer is: When a patient had several chronic
conditions, which patients had higher risks of developing T2DM than others? As previously
mentioned, EHR is a longitudinal record, and T2DM is a time to event question. Survival analysis
is the best method to answer the question. A chronic condition can vary by time; the traditional
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survival analysis cannot be workable. This is why I adopted the Cox time-varying model to answer
it. I stratified the whole population into three subgroups—younger adults, middle-aged, and older
adults—over two datasets. In UTP datasets, chronic pancreatitis is the number one risk factor in
young adults. Based on current research, recently, some experts defined a new type of diabetes
called type 3c DM. Chronic pancreatitis, cystic fibrosis, and pancreatic resection cause type 3c
DM[185]. In this research, the prevalent age group of chronic pancreatitis was middle-aged people,
which is not consistent with the result; this implies we need more research. The younger adult
patients in CHF with cystic fibrosis had the highest risks of developing T2DM, which meets the
description of the research[185]. Another study indicated that type 3c might happen at any age
along with nutrition deficiency, such as Vitamin D deficiency, and with presenting osteoporosis
or osteopenia [186]. Based on the findings, we can conclude that we need more research for type
3c diabetes in younger adults because this type of DM does not separate currently from T2DM in
this research.

Chapter 4.2: Examination of the Variables Learned by Machine Learning
Chapter 4.2.0: Introduction
I also used permutation importance to evaluate the variables learned by machine learning (ML)
methods and extraction; some of them were reliable for further examination. Considering the
guideline effects, which can cause undiagnosed diabetes, which might corrupt the reliability of the
model, I set up an experiment to indicate its effects.
Chapter 4.2.1: Methods
Chapter 4.2.1.1: The Evaluation of Variable Importance
One of the challenges of implementing current machine learning algorithms over the real clinical
world is not on the performance of the model but on what kind of information is utilized by the
model. In this dissertation, I used three types of temporal representation, which can learn a portion
of information from data. The weight matrix from machine learning algorithms can indicate the
importance of a variable related to T2DM or not. Because this is a binary classification problem,
the weight above zero is supposed to correlate with T2DM while below zero is not related to T2DM.
Continuing from the previous performance results, I chose the weight matrix from logistic
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regression to extract variable information from non-temporal representation and interval temporal
representation. The embedding layer is the layer of deep learning models that used to represent the
high dimensional inputs from datasets. Extracting the information from the embedding layer can
represent what a deep learning model learns from the dataset. Each type of temporal representation
chose the top 5% of variables and extracted data from the original dataset. The data was separated
into two parts: categorical variables including ICD-9-CM/PCS codes, medications, and procedures
and numeric data, such as laboratory results and vital signs. All of them ran on permutation
importance separately and chose eighty percent higher than the null distribution. The final two
figures represented the important variable, which might be used for further discussion regarding
the clinical meanings.
Chapter 4.2.1.1: The Evaluation of Some Possible Lab Tests for T2DM Screening
I conducted an experiment to determine whether a clinician being given abnormal lab results would
consider this an indication to perform HbA1c on a patient. HbA1c is the regular test for diagnosing
T2DM, so if the abnormal lab results cannot remind clinical practitioners to perform HaA1c tests,
those patients might become undiagnosed T2DM patients. If the proportion of undiagnosed T2DM
is high, this will corrupt the reliability of the model. There were several considerations before this
experiment. The first is the index date for the patients. The index date for non-T2DM patients is
the last visit, and for the T2DM patients, it is the first date when they started T2DM medications,
received the T2DM diagnosis, or had a finding above the threshold plasma glucose. I collected the
information within one year before the index date for a given lab test. The violin plots ( Figure 31Figure 40) are to present the distribution of a given lab test. A threshold of the lab test is set up to
separate normal and abnormal results. I calculated the relative risk of T2DM when patients already
had abnormal lab test results. The relative risk was calculated by following four groups: 1) age
above twenty; 2) age above twenty and below forty; 3) age above forty and below sixty; and 4)
age above sixty. I normalized the relative risk of the group with age over twenty as one and
compared it to the other three groups. Then, I calculated the relative risks of the four previously
mentioned age groups that received HbA1c tests and did not receive HbA1c tests within one year
before the index date. If the relative risk of the group receiving the HbA1c tests is higher than the
group not receiving HbA1c tests, it implies that the abnormal records of this lab test might be
associated with HbA1c tests under current clinical settings. If not, it is irrelevant to current clinical
settings.
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Chapter 4.2.2: Findings
Chapter 4.2.2.1: The Results of Variable Importance
From the results of the permutation test of categorical data, it is recommended that people with
several known risk factors such as hypertension (HTN), hyperlipidemia disorder (HLD), and
obesity should be screened. Some highly correlated risk factors like chronic heart disease (CHD)
and non-cardiac congenital disorder were also selected. Some signals were needed for further
investigation such as other abnormal blood chemistry (OABC), vitamin D deficiency, and fever,
among others. Some of them might be worthy of researching, and others might not be (Figure 29).
In lab and vital signs, HbA1c and glucose were the top two variables associated with T2DM. Some
variables such as absolute lymphocyte count, alkaline phosphatase, prothrombin time (PPT),
creatinine serum, and glomerular filtration rate were usually tested but currently are not listed in
the ADA primary care diabetes screening guideline. Triglyceride serum and HDL serum were both
reliable indicators for supporting performing HbA1c on patients (Figure 30).
Figure 29.Permutation Importance Results-Categorical
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Figure 30.Permutation Importance Results-Numeric
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Chapter 4.2.2.1: The Results of Some Possible Lab Tests for T2DM Screening
Figures 32 and 33 are HDL and Triglycerides (TG). In the violin plots ( Figure 31-Figure 40),
T2DM patients had higher TG and lower HDL, and younger adults (20<=age<=40) had higher
relative risks in TG, which is above 200 milligrams per deciliter and HDL below 40 milligrams
per deciliter. The group undergoing HbA1c test had higher relative risks compared with the group
did not take HbA1c test. This implies that when clinical practitioners see abnormal results from
both tests, they usually order HbA1c within the same period that is suggested by the guideline.
This is why the relative risks are higher in the HbA1c group than in the non-HbA1c group.
When we move forward to thyroid-stimulating hormone (TSH) (Figure 34) and lymphocyte count
(Figure 35), patients had abnormal results, and relative risks were higher in younger adults than in
other groups. Lower relative risks were identified in groups that did not receive HbA1c tests. This
implied that the current clinical system might consider the abnormal signal of the two lab tests as
worthy of HbA1c testing to some extent. However, this idea needs further examination.
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Young and middle-aged adults with abnormal SGOT, above 147 units per liter (Figure 36), or
SGPT, above 55 units per liter (Figure 37), easily received T2DM diagnosis within one year, and
most of the patients did not undergo HbA1c test in the same period. This result implied that the
current clinical system did not consider them as the signal for HbA1c testing. Without the HbA1c
test, we could not correctly examine the present or future risks of T2DM. This result also indicated
that SGOT and SGPT might be a new proxy for further exploring the criteria for HbA1c screening.
In albumin serum (Figure 39) and creatinine (Figure 38), serum presented a similar pattern like
SGOT and SGPT if the patient who had abnormal records (creatinine: above 1.2 milligrams per
deciliter; albumin: above 5.5 grams per deciliter) received less HbA1c screening. Behind this
phenomenon, there might be some reasons for further explanation. Glomerular filtration rate (GFR)
(Figure 40, 41) is an indicator to examine the renal function. In our results, it also showed the same
pattern as creatinine and albumin. We also need to take into account that the average value of the
two groups is lower than the standard threshold (90 milliliters per minute per 1.73 square meter).
It might imply when patients receive this lab test with some abnormal renal function.
Figure 31. Results of TG
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Figure 32. Results of HDL

Figure 33. Results of TSH

Figure 34. Results of Lymphocyte Count
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Figure 35. Results of SGOT

Figure 36. Results of SGPT

Figure 37. Results of Creatine
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Figure 38. Results of Albumin

Figure 39. Results of GFR-1

Figure 40. Results of GFR-2
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Chapter 4.2.3: Discussion
From the results in Figure 29, I found some of the medical conditions learned by ML were merged
with the high-risk conditions based on survival analysis. For example, Vitamin D deficiency is one
types of symptoms of malnutrition. The reason is in each type of temporal representation; we used
all available information. Using full information can improve performance but can also introduce
unnecessary information. The unnecessary information not only can reduce the performance of the
model but also can lead to a model which is hard to interpret. In the future, using the survival
analysis to identify some high-risk conditions and selecting the related variables might be more
helpful.
Figure 30 presents some lab tests that might be useful for the prediction of T2DM and non-T2DM.
Based on the information from Figure 30, I chose several variables for further analysis. From the
results, I found that the risk factors such as hyperlipidemia (Figure 32) or a low proportion of HDL
(Figure 33) recommended by the ADA usually remind clinicians to order HbA1c tests for
screening. This is why the relative risks of the variables are higher in patients who have completed
HbA1c testing than in patients who have not. TSH is usually considered with metabolism [187],
which is one of the risk factors associated with T2DM. This is why TSH has a pattern that is similar
to that of hyperlipidemia. Other abnormal lab results from SGOT, SGPT, creatinine, and GFR
cannot remind the real clinical world to screen patients who might be at higher risk than
undiagnosed patients because these are not included in the current screening guideline. But we
still need to do further research on how to use these tests.
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Chapter 5: Conclusions, Limitations, Synthesis, and Future Work
Chapter 5.1: Conclusion
Chapter 5.1.1: The Conclusion of Temporal Representation
For the performance of two testing schemes and three types of temporal representations,
continuous representation performs better than, the other two types of temporal representations in
the cutting time points scheme. For the random splits scheme, our seq2seq model had a better
performance than the other two widely used models—one is RNN, and the other one is RETAIN.
To realize the extra data effects more, which means more years of data in the encoder, I made a
threshold wherein a patient must have at least three years of data in the encoder. From the result,
the patient had a better performance than those with less data in the encoder. Besides, I used MAE
to measure the early detection of T2DM patients in the seq2seq model, which presented the larger
dataset with a better performance. In the research, I want this model not only to predict whether
the patient had T2DM or not, but also when this patient had T2DM. To achieve this goal, I adapted
the time ROC to measure it. The results presented an interesting phenomenon where the seq2seq
model without attention mechanism in the encoder or decoder had a better performance. In addition,
the noise in the larger dataset, which came from patients that had shortened periods of records,
decreased the performance of the model. There were many reasons why the patient did not have
enough data for this analysis and research.
Chapter 5.1.2: The Conclusion of the Information Learned by Data
This research also wants to determine how the machine learning algorithms learned from the data
and the difference between the information learned by the machine learning algorithms and the
information learned by traditional biostatistics. The traditional biostatistical method such as
logistic regression and survival analysis had been widely applied to data analysis to summarize
some information, which can suggest some modifications of guideline or policy changes. The
machine-learning algorithms, on the other hand, learned the patterns in the data and used the
pattern to predict the patients’ risks. This research also wants to identify this gap and point to an
alternative direction to solve this problem and make machine learning applicable to the real clinical
world in the future. T2DM is a chronic disease, and before developing it, patients underwent some
conditions that contribute to developing T2DM. Chronic condition indicators can catch those
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conditions. Using chronic condition indicators, we can demonstrate what kinds of chronic
conditions were more prevalent in the development of T2DM by using survival analysis. In the
survival analysis, we found the most critical chronic conditions among different age groups were
different in the two datasets. The difference implied that the local group had significantly different
characteristics from the nation-wide group. This might imply that the model training based on the
local dataset cannot be used in the national dataset. However, the difference is useful for building
the prevention policy for intervention. In the future, when we want to design a model for clinical
usage, the difference might assist us in estimating the changing algorithm effects.
Chapter 5.1.3: The Suggestion for Considering the Guideline Effects
For testing this assumption, I used the results of lab tests within one year before the index date. I
also tested some lab results which were based on temporal representations; the models believed
those variables were highly associated with T2DM. From the results, TG and HDL meet my
assumptions. TSH is the variable that is not listed in the recommendation guideline but still has
high relative risks in patients who had HbA1c tests rather than patients without the HbA1c test.
The result indicates that clinical practitioners seeing the abnormal results of TSH might order the
HbA1c test in the same period. The results cannot explain why and how they do this, but we can
further research this phenomenon. GFR, albumin, creatinine, SGOT, and SGPT presented lower
relative risks in patients with an HbA1c test than patients without the HbA1c test; this implies that
abnormal results with those two tests do not urge clinical practitioners to order HbA1c. We can
further infer that ignoring those abnormal signals might cause undiagnosed T2DM. The patients
with undiagnosed T2DM might corrupt the data reliability and cause more noise in the model.

Chapter 5.2: Limitations
Except for the differences in the dataset, we need to consider that another issue is the guideline.
The guidelines construct the screening process, which determines the classification of the label.
The ADA T2DM screening guideline recommends that patients over 40 with some symptoms,
such as hypertension or hyperlipidemia, are worthy of receiving HbA1c screening. This means
that patients with other abnormal lab tests usually did not receive HbA1c screening. Besides,
HaA1c is the lab test for diagnosing T2DM. The guideline based on this might lead to undiagnosed
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T2DM, which will make the prediction model lose focus on some T2DM-related information and
further reinforce the bias.

Chapter 5.3: Synthesis
In this research, I found some possible risk factors associated with T2DM. Chronic pancreatitis is
the top risk factor in young adults in this research. Based on current research, some experts defined
a new type of diabetes called type 3c DM. Type 3c DM is caused by chronic pancreatitis, cystic
fibrosis, and pancreatic resection[185]. In this research, the prevalent age group of chronic
pancreatitis comprised middle-aged people, which is not consistent with the result. This suggests
that we need more research. The younger adult patients in CHF with cystic fibrosis had the highest
risk of developing T2DM, which meets the description of the research[185]. Another study
indicated type 3c might happen at any age by accompanying nutrition deficiency, such as Vitamin
D deficiency, and presenting osteoporosis or osteopenia [186]. Based on the findings, we can make
a conclusion that for type 3c Diabetes in younger adults, we need more research because this type
of DM currently is not separated from T2DM.
The association between TB and T2DM is still an interesting question. Some researchers focused
on patients with T2DM likely to develop TB rather than developing TB first then developing
diabetes[188]. In this research, I still hold the question about this association because I did not find
the same pattern in the CHF. It might be a local issue (Texas only) or some problem with data
collection.
Liver diseases still have a strong correlation with the development of T2DM, but this lacks
substantial evidence[189]. Recently, research pointed out non-alcoholic fatty liver disease
(NAFLD) and type 2 diabetes (T2DM) are common conditions that regularly co-exist [190]. This
is an interesting question to answer determining whether liver disease causes T2DM, or is just a
side-effect of T2DM; this is still a question. Our dataset is limited by the data collection method,
which cannot answer this question.
Chapter 5.4: Future Work
The Food and Drug Administration (FDA) recently opened a panel to discuss the regulation of
Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD)[191]. In FDA’s
definition, SaMD is software independent from the hardware medical devices for achieving some
76

medical purpose, including treatment, diagnosis, cure, and mitigating or preventing diseases or
other conditions[191]. One of the issues of AI/ML that the FDA is concerned with is the model
retraining. From the traditional perspective, the medical device can generally work on the
condition that it is FDA recognized and approved. The AI/ML models are data-driven applications,
and EHR data is recognized as full of bias and errors. Additionally, bias and errors are also affected
by education and the culture of an organization. This means that the AI/ML model needs to retrain
in the new environment. The process of retraining can alter the weight of variables, the contents
of AI/ML, and cannot prove to the FDA that the retraining model is the same as reported in the
pre-market submission. The FDA is skeptical about this process because it might affect the model
reliability, especially of some models that are based on the neural network. To resolve this issue,
the FDA proposed a framework that requires SaMD not only to provide the pre-market document
for demonstrating its effectiveness and safety but also to give the expected algorithm’s changed
protocol after retraining. The American Medical Informatics Association (AMIA) generally agrees
with the FDA’s proposed framework but approves of more advanced regulation of continuous
learning algorithms (deep learning). AMIA also advocates determining how to control the new
data input because this will alter the contents of the AI/ML model and how the knowledge will
affect the data collection process, which will change the dataset for retraining [192].
From this perspective, the future of medical AI should be based on more reliable datasets such as
those found in certified EHRs. The certified EHR contains the standardized data element. Even
though the data element might be different in different hospitals, under the same standards, we can
estimate the differences and design some experiments to test how those differences may or may
not affect our models.
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